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Cannabis is an annual, dioecious plant, more rarely monoecious, native to 
central Asia. Cannabis most likely originates from Neolithic China and its 
preparations were known to the ancient Assyrians, Scythians, Chinese, Indians, 
and Persians. However the complete history of domestication is not known but 
the first known evidence of the use of cannabis as a medicine was found in 
China 500 years ago (Hanuš and Mechoulam 2005).  Preparations of cannabis 
have been used by man for their euphoric effects for over 4000 years (Uhl 
2006). More than 700 varieties of Cannabis have been reported, however, the 
species and chemotaxonomic classification of this plant is quite controversial. 
Schultes et al. (1974) described three putative varieties of cannabis, Cannabis 
sativa L. (tall branched plants for fiber, seed and psychotropic use), Cannabis 
indica Lam. (short, broad leaflets plants utilized to produce hashish), Cannabis 
ruderalis Jan. (short, unbranched road side plants).  More recently, de Meijer 
developed a classification system of cannabis based on the cannabinoid contents 
(de Meijer et al. 2003). For forensic and legislative purposes, the cannabis types 
are classified into the drug types and the fiber types (Hazekamp and Fischedick 
2012). This classification is based on the contents of the psychoactive 
cannabinoid Tetrahydrocannabinol (THC). The ratio (THC + CBN)/CBD is 
determined for identifying the phenotypes of cannabis plants (Fetterman et al. 
1971). If the ratio found is greater than 1, the cannabis variety is classified as 
drug type; if it is less than 1, it is a fiber type. More simply, cannabis strains 
cultivated for fiber and/or seed purposes (with low content of THC) are referred 
as fiber type, while the strains cultivated for medicinal or recreational use (with 
high content of THC) are recognized as drug  type (Hillig and Mahlberg 2004, 
Hossein and Isaac 2007).  
The basic material of all the cannabis products is the plant Cannabis sativa L. 
(Hazekamp 2007). Therefore, in literature more often, the variety C. sativa L. 




cannabis and vice versa. Cannabis sativa encompass both drug and nondrug 
varieties. Nondrug varieties are called hemp and drug varieties are referred to as 
marijuana (Hossein and Isaac 2007). The enormous number of products derived 
from C. sativa have greatly increased the attention for the chemistry and 
pharmacology of the plant. The demand for hemp  made products is increasing 
in the global market, including fibers hemp leaves, hemp seed derivatives, oil, 
flour, beverages (beer, lemonade and liqueur) and cosmetic products 
(Lachenmeier et al. 2004). Hemp is becoming the centre of attention for 
sustainable economic development in USA (Tun 2005).  The medicinal 
applications of marijuana are also intensively investigated. A large number of 
clinical reports favor the use of marijuana as an effective remedy against e.g. 
central thalamic pain, dystonia, familial Mediterranean fever, multiple sclerosis, 
chronic pain, depression, anxiety, migraine and sleeping difficulties (Ware et al. 
2005). Cannabis sativa  is a rich source of a variety of compounds; more than 
500 chemical compounds have been identified in this plant, including 
cannabinoids, terpenoids and flavonoids. The synergism between these 
compounds might play a role in the therapeutic potential of cannabis (Stott and 
Guy 2004). 
The term “cannabinoids” represents a group of C1, C3 and C5 side chains 
terpenophenolic compounds only found until now in C. sativa (Cannabaceae). 
The highest concentration of cannabinoids is present in resinous form in the 
buds and flowering tops of the female plants (Mechoulam and Goani 1967). 










-THC) (El-Sohly 2006) were extensively 
studied and found to possess a variety of potentially useful pharmacological 
activities in addition to the psychotropic effects for which cannabis is well 




sativa have many distinct therapeutic properties (Sirikantaramas et al. 2007). 
The analgesic, anti-emetic, anti-oxidative, neuroprotective and anti-
inflammatory properties could be helpful in the treatment of many neurological 
disorders (Carter and Weydt 2002). Physiological actions as anticonvulsant, 
antidepressant, hypotensive, bronchodilation and lowering of intraocular 
pressure have led to a number of investigations on the possible development of 
useful medicines from the naturally occurring and synthetic cannabinoids. The 
∆
9
-THC is the psychoactive component of the cannabis plant (Scotter et al. 
2010), while the major non psychoactive constituents include CBD, CBN, 
cannabigerol (CBG) and cannabichromene (CBC) (Gaoni and Mechoulam 
1966). In the plant these compounds occur in their respective acidic form. i.e. 
having a carboxylic acid group. The acidic cannabinoids, which are non–
psychotropic, undergo decarboxylation upon heat treatment (e.g. smoking) to 
yield the physchotropic cannabinoids.  
The ∆
9
-THC is known to be responsible for the main psychotropic effects of the 
cannabis made preparations (Ashton 2001).  It was first identified in 1964 by 
Mechoulam and Gaoni (Gaoni and Mechoulam 1964). Sometimes, ∆
9
-THC is 
used as a marker in evaluating the drug intensity of various cannabis based 
preparations (hashish, marijuana, hash oil) (Gambaro et al. 2002). The ∆
9
-THC 
acts on the central nervous system (CNS) and caused euphoria, relaxation, 
tachycardia and alteration in blood pressure; hallucinations also appear at high 
doses (Pellegrini et al. 2005). It has been used in a number of disease states (e.g. 
pain, anxiety, asthma, glaucoma, and hypertension) (Abbott et al. 1977). ∆
9
-
THC mediates many of these effects by acting on the cannabinoid receptor type 
1 (CB1) (Tseng and Craft 2004, Varvel et al. 2005). The synthetic ∆
9
-THC is 
being prescribed with the brand name “Marinol”. In 1986, the U.S food and 
drug administration (FDA) approved Marinol for the treatment of nausea and 




drug to treat loss of appetite and weight loss in patients infected with HIV (the 
virus causes AIDS). A U.K based company (GW Pharmaceuticals) sells the 
drug named Sativex, which contains the two best known cannabinoids, ∆
9
-THC 
and CBD. Sativex has been approved in Canada, New Zealand and eight 
European countries. This drug is effective against muscle spasms associated 
with multiple sclerosis (MS), cancer and neuropathic pain.    





-THC has been approved by FDA and is 
being marketed to the pharmacies of U.S.A and Canada. But still the poor water 
solubility of ∆
9
-THC is an issue which needs to be addressed. ∆
9
-THC is a 
lipophilic compound and only slightly soluble in water. The human body 
contains high lipid contents, which are not only the body fats but also present in 
brain and cell membranes. Lipid-soluble drugs leave the blood rapidly and tend 
to accumulate in the fatty tissues (Hollister 1998). Likewise, ∆
9
-THC binds 
strongly to plasma protein and other fatty tissues, which prolongs its release 
from the body (Paton 1975). The intravenously administered ∆
9
-THC to a 
human can persists longer than three days in the plasma and its metabolites can 
be detected in the urine or feces even for 8 days (Kanter and Hollister 1977, 
Lemberger et al. 1970). Although, there is no report of continuing effects of the 
drug, the long persistence of ∆
9
-THC in the body and the slow clearance of its 
metabolites might cause side effects. So, there is a need to structurally transform 
the compound to increase its polarity and its rapid release from the body.  
Biotransformations are the chemical reactions carried out by cells, organs and 
enzymes. These reactions are used to structurally modify the compounds by 
exploring the unique properties of biocatalysts (Giri et al. 2001). ∆
9
-THC was 
transformed into a number of new derivatives by using mammalian enzyme 




pharmacokinetics. Mammalian transformations were useful to reveal the various 
metabolic pathways of ∆
9
-THC in different mammalian species, but for the 
industrial scale production of the potential compounds by means of mammalian 
cell culture or tissue culture is too expensive to develop cannabinoid based 
drugs. Microorganisms may perform similar biotransformations as mammalians 
and could be suitable source for large scale production of new cannabinoids.  
The biotransformation potential of microorganisms and their enzymes for the 
production of new modified compounds is well acknowledged. The attractive 
characteristics of microorganisms make them favorable for biotransformation 
studies because of reduction in the number of animals used, ease of setup and 
manipulation (can easily be scaled up), and maintenance of stock cultures is 
simple and cost effective. Plants are able to produce a number of different 
chemicals which cannot easily be produced by synthetic means. Plant cell 
cultures are used to produce a variety of secondary metabolites including 
phenolics, steroids, alkaloids, coumarins and terpenoids. Plant enzymes act as 
unique biocatalysts and can successfully transform exogenous substrate to novel 
substances.  Microorganisms and plant cell cultures have successfully produced 
new cannabinoids, which are structurally similar to the compounds obtained 
from mammalian transformations (This thesis). The only need is to scale up the 
production of these metabolites for further bioassays, clinical studies and 
potential commercial uses. 
The zebrafish embryo is emerging as a prominent model of developmental 
biology, for disease studies and for drug discovery. A number of unique 
characteristics of the zebrafish embryo makes it an attractive model:  small size, 
ease of maintenance, rapid development, large number of offspring, small 
amount of compound required for testing, and its optical transparency (Dahm 
and Geisler 2006). The embryos hatch approximately 2-3 dpf (Days post 




(Rubinstein 2003). The transparency of embryos and young larvae provide 
insight in the organ formation and their functions in developmental processes 
(Schwerte and Fritsche 2003). This optical transparency and access to all the 
developmental stages give an opportunity to study developing pathologies at 
different stages (Lieschke and Currie 2007).  Genome sequencing has revealed a 
great deal of homology between the zebrafish and other vertebrates (including 
humans) (Schwerte and Fritsche 2003). A number of sophisticated mutagenesis 
and screening approaches have been developed in zebrafish embryos and made 
it a model of choice for the study of a wide variety of human diseases. Different 
protocols and automated imaging systems have been established for the 
behavioral analyses of zebrafish larvae. These systems produce a large set of 
data and facilitate high-throughput genetic, pharmacological and environmental 
screening (Creton 2009). A range of simple sensorimotor responses appear in 
the early developmental stages of the zebrafish larvae. These features represent 
the brain development and are useful for behavioral investigations (Souza and 
Tropepe 2011).  
The zebrafish larvae are not only useful for high throughput analyses or acute 
toxicity but also helpful to understand the mechanisms of toxicity and possible 
adverse and long term effects of hazardous chemicals.  The effect of added 
chemical entities finally leads to an alteration in gene transcription and protein 
expression, which ultimately affects the metabolic profile of the organism. 
Metabolites are the final product of gene expression and metabolomic profiling 
leads to the understanding of possible important events taking place in a cell, 
tissue or organism (Hayashi et al. 2011). A qualitative and quantitative 
measurement of all the metabolites present in a system at a particular time is 
called Metabolomics. Metabolomics, together with transcriptomics and 
proteomics, reflects the condition of the system and may show e.g. the effect of 




fingerprinting has been successfully introduced in zebrafish larvae to predict 
different embryonic stages (Hayashi et al. 2011, Hayashi et al. 2009). A multi-
analytical approach (including 1H NMR, GC/MS and LC/MS) was also used to 
study the biochemical profile of livers of male and female zebrafish (Ong et al. 
2009).     
The CB1 (Lam et al. 2006) and CB2 (Rodriguez-Martin et al. 2007) receptors 
have been identified in zebrafish. A high level of sequence conservation of the 
CB1 receptor has been shown for zebrafish and mammals (Lam et al. 2006). 
Involvement of the CB1 receptor is also reported in the hatching process of 
zebrafish embryo (Migliarini and Carnevali 2009). The cannabinoid receptors in 
zebrafish embryos can help in studies to gain further insight in the 
pharmacology of cannabinoids and it might also be helpful to resolve some 
unclear features of the cannabinoids mode of action, like the phenomenon of 
tolerance and dependence caused by cannabinoid based drugs (Rodriguez-
Martin et al. 2007).  
Aim of the thesis 
The aim of the present study was: 
- To investigate the potential of bacterial strains and plant cell cultures to 
produce polar derivatives of ∆
9
-THC. 
- To examine the possibilities of using the zebrafish embryo to screen for 
cannabis receptor affecting compounds. 
For the biotransformation, a library of microorganisms able to survive on 
hydrocarbons was available for screening. Methods for the analysis of 
cannabinoids and their metabolites and for their isolation and structure 




For the zebrafish screening the developmental, behavioral and metabolic effects 
of known cannabinoids in zebrafish embryos by using whole mount staining, 
visual motor response test needed to be explored. Furthermore a novel systems 
biology approach, using metabolomics was developed to study the effect of the 
cannabinoids.  
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Cannabinoids are terpenophenolic compounds consisting of an aromatic 
polyketide and derived from the geranyl diphosphate C10 terpenoid unit. They 
are the active constituents in Cannabis sativa and have been utilized in a 
number of cannabis-based medicines. Biotransformation of cannabinoids is an 
important field of xenobiochemistry and toxicology and the study of the 
metabolism of these compounds can lead to the discovery of new compounds, 
unknown metabolites with unique structures and new therapeutic entities. 
Different fungi, bacteria, plants and animal cells have been used for the regio- 
and stereoselective transformation of cannabinoids. All of the above mentioned 
organisms have distinct enzymes which catalyze the conversion of a specific 
cannabinoid at different positions and thus provide a variety of derivatives. All 
organisms are able to transform the alkyl side chain where as mammalians are 
unique in the formation of the carboxy derivatives. This review article assesses 
the current knowledge on the biotransformation of ∆
8
-THC, CBN, CBD with 




Pharmacological properties of cannabis are well known and documented in 
literature (Carter and Weydt 2002; Russo 2007). The term “cannabinoids” 
represents a group of C1, C3 and C5 side chains terpenophenolic compounds 
found until now only in Cannabis sativa L (Cannabaceae) (Mechoulam and 
Goani 1967). Cannabinoids, the active compounds in C. sativa (Sirikantaramas 
et al. 2007) have distinct therapeutic properties. After the purification and 










-THC) (Fig. 1) were extensively 
studied and found to possess a variety of potentially useful pharmacological 
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activities in addition to the psychotropic effects for which cannabis is well 
known (Monique and Stephen 1976). Such physiological actions as 
anticonvulsant, anti-emetic, anti-oxidative, neuroprotective, anti-inflammatory, 
antidepressant, hypotensive, bronchodilation and lowering of intraocular 
pressure have led to a number of investigations on the possible development of 
useful medicines from the naturally occurring and synthetic cannabinoids. THC 
is the psychoactive component of the cannabis plant (Scotter et al. 2010), while 
the major non psychoactive constituents include CBD, CBN, cannabigerol 
(CBG) and cannabichromene (CBC) (Fig. 1) (Gaoni and Mechoulam 1966). In 
the plant these compounds occur in their respective acidic form. i.e. having a 
carboxylic acid group. The acidic cannabinoids, which are non psychotropic, 
undergo decarboxylation upon heat treatment (e.g. smoking) to yield the 
physcotropic cannabinoids. Δ
9
-THC  has been used to treat number of disease 
states (e.g. pain, anxiety, asthma, glaucoma, hypertension) but also possesses 
some undesirable pharmacological side effects (e.g. euphoria, tachycardia, etc.) 
(Abbott et al. 1977). To minimize these undesirable side effects new 
cannabinoids have been prepared by de novo synthesis (Pars and Howes 1977) 
and by chemical and microbiological conversions (Abbott et al. 1977; Binder 
and Meisenberg 1978; Christie et al. 1978; Robertson et al. 1978b) of both 
naturally occurring and synthetic cannabinoids. This review assesses the 
available information regarding the production of various compounds obtained 
from the biotransformation of cannabinoids by using different microorganisms, 
plant cells and mammalian cells. In this review the benzoypyran numbering 
system is used instead of the monoterpene numbering system (under the 
monoterpene system 
9
-THC is known as 
1
-THC) (Fig. 2).  
Biotransformation 




















   Figure. 1: Chemical structures of the major cannabinoids. 1: ∆9-THC, 2: ∆8-THC, 3:           
CBD, 4: CBN, 5: CBG, 6: CBC. 
 
                            
    
                                     Figure 2:  ∆9-THC (Benzopyran numbering system) 
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synthetic compounds into substances having specifically modified structures 
(Venisetty and Ciddi 2003). Biotransformation is a vital process for survival, in 
that it transforms absorbed nutrients into substances required for normal bodily 
functions and to detoxify xenobiotics. These reactions convert non polar 
compounds into more polar compounds, making them water soluble and more 
easily excretable for the organism (Asha and Vidyavathi 2009). In this way 
biotransformation serves as an important defense mechanism in that, toxic 
xenobiotics and body wastes are converted into less harmful substances which 
can be easily excreted from the body. The pathways of xenobiotic metabolism 
can be divided into phase І and phase II reactions. Phase I includes oxidative, 
reductive and hydrolytic reactions. In these reactions, a polar group is 
introduced, so the molecule becomes more polar and thus improves excretion 
from the cell/or body. In phase II, polar endogenous molecules like glucoronic 
acid, sulfate, glycine, glutathione etc. are attached to form highly water soluble 
substances. These reactions are known as conjugation reactions (Smith and 
Rosazza 1983).    
 Active metabolites obtained from biotransformation 
Plant, animal, microbial cells and purified enzymes are being used to carry out 
specific conversions of complex substances. This approach has great potential 
to generate novel products (Giri et al. 2001).  Biotransformation reactions yield 
chemically stable metabolites which can be pharmacologically active (Baillie et 
al. 2002, Fura et al. 2004, Garattini 1985, Guengerich 2001, Kumar and 
Surapaneni 2001) and might thus significantly contribute to the therapeutic 
effect of a drug. Some of these have even been developed as drugs in their own 
right. Important examples are atorvastatin (Lennernas 2003; Williams and Feely 




fluoxetine (Cheer and Goa 2001), cetirizine (Golightly and Greos 2005) and 
fexofenadine (Golightly and Greos 2005, Meeves and Appajosyula 2003). 
In a traditional prodrug-based approach to drug discovery, biotransformation 
reactions can play a key role to convert pharmacologically inactive compounds 
to active metabolites with strong therapeutic effects through phase I (oxidative 
or reductive) and phase II (conjugative) metabolism. Some of the important 
biotransformation reactions are aliphatic or aromatic carbon hydroxylation, 
epoxidation, heteroatom oxidation (N, S, and P), reduction, glucuronidation, 
sulfation and acetylation. 
 Microorganisms in biotransformation 
The biotransformation potential of microorganisms and their enzymes for the 
production of a large library of novel metabolites is well documented (Nikolova 
and Ward 1993, Schulze and Wubbolts 1999, Ward and Singh 2000). The use 
of microbial cell cultures for transformation of natural products is favorable 
because they mimic mammalian biotransformation (Smith and Rosazza 1983). 
Microbial models offer a number of advantages over the use of animals in 
metabolism studies, such as a reduction in the number of animals used 
(particularly in the early phases of drug development), ease of setup and 
manipulation (microbial models can be scaled up easily for the preparation of 
large quantities of metabolites) and cost effectiveness. In addition, methods for 
genetic modification of microbes are well established (Rathbone and Bruce 
2002). Microbial strains with specific properties for certain chemical 
conversions may be selected or even engineered for stereoselective and 
regiospecific conversions (Abourashed et al. 1999, Demain 2000, Rathbone and 
Bruce 2002, Smith and Rosazza 1983). The maintenance of stock cultures of 
microorganisms is also easier and cheaper than the maintenance of mammalian 
cell and tissue cultures or laboratory animals. Microorganisms can also be 
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utilized to perform reactions which are difficult to perform chemically 
(Venisetty and Ciddi 2003).  
 Plants and plant cells in biotransformation 
Plants are able to produce a number of diverse biochemicals including drugs, 
flavors, pigments and agrochemicals which cannot easily be achieved by 
synthetic means. Plant cell cultures have great ability to produce specific 
secondary metabolites like a wide variety of chemical compounds including 
aromatics, steroids, alkaloids, coumarins and terpenoids. Production of 
secondary metabolites and the biotransformation of precursor compounds by 
plant tissue cultures may lead to both the synthesis of valuable substances and 
elucidation of their biosynthetic pathways (Berlin et al. 1989, Loh et al. 1983). 
Production and accumulation of plant specific secondary metabolites are not 
always possible in plant cell cultures. However such cultures may retain an 
ability to transform exogenous substrates into products of interest. Plant 
enzymes act as suitable biocatalysts to perform complex biochemical reactions 
(Giri et al. 2001). The chemical compounds, which can undergo 
biotransformation by plant enzymes, are diverse in nature (Franssen and Walton 
1999) and are not necessarily natural intermediates in plant metabolism but can 
also be of synthetic origin (Pras et al. 1995). Plant cell cultures and enzymes 
have thus the potential to transform substances, such as industrial byproducts, 
into novel, valuable products. Plant biotransformation systems can be used 
alone or in combination with organic synthesis to produce novel chemicals.  
Biotransformation of cannabinoids 
Biotransformation of cannabinoids by mammalian cells 
Extensive in vivo and in vitro studies have been carried out on the 




Tetrahydrocannabinol (THC) and other cannabinoids are shown to be good 
substrates for cytochrome P450 (CYP450) enzymes because of their 
hydrophobic properties (Yamamoto et al. 1995). Mammalian CYP450s 
metabolise Δ
9
-THC into a number of new compounds. Many oxidative 





-THC, 8β,9β-epoxyhexahydrocannabinol (EHHC), 
9α,10α-EHHC and 3'-hydroxy-∆
9
-THC (Table 3) are pharmacologically more 
active than THC (Yamamoto et al. 2003).  
Metabolism of THC in humans 
The metabolism of ∆
9
-THC and related cannabinoids in human has been studied 
by utilizing parenteral, oral, and smoking as a route of administration. The 
general pattern of metabolism is the same in all cases with as major metabolic 
reactions the formation of an 11-hydroxy derivative and as minor product the 8-
hydroxy derivative (Wall and Perez-Reyes 1981). The monocarboxylated 
derivatives have been isolated from human urine (Table 3, compound 20 and 
23), further side chain carboxylated and their hydroxylated derivatives occur 
and were also found in urine (Table 4, compound 27, 28, 29, 30, 31, 32, 34, 35, 
36, 37, 39) (Halldin et al. 1982a, Halldin et al. 1982b). Among the acid 
derivatives,   Δ
9
-THC-11-oic acid (Table 3, compound 20) (Halldin et al. 1982b, 
Kanter and Hollister 1978), 4',5'-bisnor-Δ
9
-THC-11,3'-dioic acid (Table 4, 
compound 35) (Halldin et al. 1982a) and Δ
9
-THC-11-oic acid glucoronide (Fig. 
3a) (Williams and Moffat 1980) are identified as the major  metabolites in 
human urine.  In vitro human liver metabolism yields 8α-hydroxy- (Table 1, 
compound 2) (Bornheim et al. 1992, Widman et al. 1979), 11-hydroxy-, 8β-
hydroxy- (Table 1, compound 1, 3) (Bornheim et al. 1992, Halldin et al. 1982c, 
Wall et al. 1972, Widman et al. 1979), traces of 11-hydroxy-
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epoxyhexahydrocannabinol (11-OH-EHHC) (Fig. 3b) (Halldin et al. 1982c) and 
8-keto-∆
9
-THC (Fig. 3c) (Bornheim et al. 1992). 
OH
O R
Δ9- Tetrahydrocannabinol,                    R= n-C5H11
n-hexyl- Δ9- Tetrahydrocannabinol R= n-C6H13
Δ9-Tetrahydrocannabivarin,                   R= n-C3H7














Figure 3: a; Δ9-THC-11-oic acid glucoronide b; 11-hydroxy-EHHC c;  8-keto-∆9-THC 
d; Derivatives of THC  e; 11-oxo- ∆9- THC.  
 
Metabolism of THC in rabbits 
After in vivo administration of the ∆
9
-THC to rabbits, a number of mono- and 
dihydroxy derivatives  (Table 1 ,2) (Nordqvist et al. 1979a), monocarboxylic 
acid (Table 3, Compound 20) and side chain acids (Table 4, compound 26, 27, 
29, 31, 32, 33, 34, 35, 38, 39) (Burstein et al. 1972, Nordqvist et al. 1979a) were 






(Table 4, compound 35) as a major compound (Nordqvist et al. 1974). 
Furthermore, three side-chain monocarboxylic acids hydroxylated in the allylic 
position in the isoprene moiety were also identified as O-glucuronide in rabbit 
urine (Nordqvist et al. 1979b). Rabbit in vitro liver microsomal metabolism of 
∆
9
-THC formed 11-hydroxy- (Table 1, compound 1) (Burstein and Kupfer 
1971a, Nilsson et al. 1970; Wall et al. 1970) and 8α-hydroxy-∆
9
-THC (Table 1, 
compound 2) (Benzvi and Burstein 1975). Microsomal oxygenase was found to 




-THC (Watanabe et 
al. 1979). 
Table 1. Monohydroxylated metabolites of ∆9- THC. (1) man, (2) rhesus monkey, (3) 
mouse, (4) rat, (5) rabbit, (6) guinea pig, (7) dog, (8) microorganisms. 
            Species             References 
No    Position           
OH    of OH                     
1 2 3 4 5 6 7 8  
1      11-OH + + + + + + + + (Burstein and Kupfer 1971a, Burstein and Kupfer 
1971b, Matsunaga et al. 1995, Nilsson et al. 1970, 
Wall et al. 1970) 
2       8α-OH + + + + + + + + (BenZvi et al. 1974, Harvey and Paton 1976, Jones et 
al. 1974, Matsunaga et al. 1995, Wall et al. 1972, 
Widman et al. 1975a) 
3        8β-OH + + + + + + + + (Harvey et al. 1977, Matsunaga et al. 1995, Wall 
1971, Wall et al. 1972, Widman et al. 1975a)  
 4       1’-OH − − − − − + − + (Binder and Popp 1980, Harvey et al. 1978b, Harvey 
et al. 1980a) 
 5       2‘-OH + − − − − + − +  (Binder and Popp 1980, Halldin et al. 1982c, Harvey 
et al. 1978b, Harvey et al. 1980a)  
 6       3‘-OH − − + + + + + +  (Binder 1976, Christie et al. 1978, Harvey et al. 
1977, Harvey et al. 1978b, Harvey et al. 1980a, 
Widman et al. 1975a) 
 7       4‘-OH −  − + − − + + + (Binder 1976, Binder and Meisenberg 1978, Binder 
and Popp 1980, Harvey and Paton 1978, Harvey et al. 
1980a, Robertson and Lyle 1975, Widman et al. 
1975a) 
 
Metabolism of THC in mouse 
 Harvey and Paton (1978) identified multiple substituted metabolites formed by 
in vivo metabolism of ∆
9
-THC in the mouse liver among which, 11-; 2'-; and 3'- 
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Table 2. Di- and trihydroxy metabolites of ∆9-THC. (1) man, (2) rhesus monkey, (3) 
mouse, (4) rat, (5) rabbit, (6) guinea pig, (7) dog, (8) microorganisms. 
  Species References 
No    Position 
of  OH                      
Groups                                                                        
1          2 3 4 5 6 7 8  
9    8α , 11-di-OH + + + + + + − −  (Benzvi Z. and Burstein 1975, Halldin et al. 1982c, 
Harvey and Paton 1976, Harvey et al. 1978b, 
Harvey et al. 1980a, Jones et al. 1974, Wall and 
Brine 1976, Wall et al. 1972)  
10   8β, 11-di-OH + + + + − + + − (Halldin et al. 1982c, Harvey et al. 1977, Harvey et 
al. 1978b, Harvey et al. 1980a, Wall and Brine 
1976)  
11    1’, 11-di-OH − + − − − + − − (Harvey et al. 1980a, Wall and Brine 1976) 
12    2’, 11-di-OH + + + − − + − − (Halldin et al. 1982c, Harvey et al. 1977, Harvey et 
al. 1978b, Harvey et al. 1980a, Wall and Brine 
1976) 
13   3’, 11-di-OH − + + + − + − +  (Christie et al. 1978, Halldin et al. 1982c, Harvey 
et al. 1977, Harvey et al. 1978b, Wall and Brine 
1976)  
14   4’, 11-di-OH + + + − − + − +  (Binder 1976, Halldin et al. 1982c, Harvey and 
Paton 1978, Harvey et al. 1980a, Wall and Brine 
1976) 
15   4’, 8α-di-OH − − − − −  − − +  (Binder 1976) 
16  1’-4’, 8β-di-OH − − − − − + − − (Harvey et al. 1980a)   
17   1’, 2’-4’-di-OH − − − − − + − − (Harvey et al. 1980a)  
18    2’-4’ ,8α,11-
tri- OH 
− − + − − + − − (Harvey and Paton 1978, Harvey et al. 1977, 
Harvey et al. 1978b, Harvey et al. 1980a) 
19    2’-4’, 8β,11-
tri- OH 
− − − − − + − −  (Harvey et al. 1980a) 
 
the monohydroxy derivatives (Table 1, compound 1, 5, 6), 8β, 11-;  2', 11-; and 
3', 11-dihydroxy derivatives (Table 2, compound 10, 12, 13 ), 2', 8α, 11- and 3', 
8α, 11- the most abundant trihydroxy derivatives (Table 2, compound 18). 
Harvey and Paton (1978) also found the formation of 2',11-, and 3',11-
dihydroxy-8-oxo-∆
9
-THC (Table 6, compound 48) in mouse liver and 4'-
hydroxylation (Table 1, compound 7) was suggested as a major metabolic route 
for the ∆
9
-THC transformation (Harvey et al. 1977). Mono- and dihydroxy- 
acids of ∆
9






(Table 3, compound 20) was identified from the mouse liver together with its 
8α- and 2'- monohydroxy derivative (Table 5, compound 41 and 43), 2',8α- and 
3',8α-dihydroxy derivatives (Table 5, compound 45) (Harvey and Paton 1976; 
Harvey et al. 1978b). In vitro mouse liver microsomes transformed ∆
9
-THC into 
11-hydroxy- (Jones et al. 1974) and 8α-hydroxy-∆
9
-THC (BenZvi et al. 1974) 
(Table 1, compound 1,2). Later on, transformation of 8α-; 8β- and 11-hydroxy-
∆
9
-THC was studied (Burstein   and Shoupe 1981), metabolism of 8α-hydroxy-
∆
9
-THC was parallel to that of ∆
9
-THC but the presence of 8β-hydroxy group 
was found to suppress the hydroxylation and oxidation at C-11 and to increase 
the β-oxidation of the side-chain (Harvey et al. 1980b).  
The in vivo metabolism of Δ
8
-THC produced three alcohols, five diols, six 
triols, five monohydroxy acids, six dihydroxy acids, two substituted ketones, an 
epoxide, three dihydroxy metabolites and a glucuronide conjugate (Harvey and 
Paton 1980). Δ
11
-THC was transformed into 26 metabolites produced by 
epoxidation among which 9α,11- and 9β,11-dihydroxyhexahydrocannabinols 





-THC) was identified from the mouse brain as a new in vivo 
metabolite of Δ
8
-THC (Watanabe et al. 1980).   
Metabolism of THC in monkey, guinea pig and dog 
Purified Cytochrome P450 isozyme of monkey metabolized Δ
9
-THC to 11-; 8α-
; 8β- and 3’- hydroxy-Δ
9
-THC (Table 1, compound 1, 2, 3, 6) (Matsunaga et al. 
1995). Moreover, Δ
9
-THC was also metabolized to some dihydroxy derivatives, 
such as 8α,11-; 8β,11-; 1’,11-; 2’,11-; 3’,11- and 4’,11-Δ
9
-THC (Table 2, 
compound 9, 10, 11, 12, 13, 14) (Wall and Brine 1976).   
Metabolism and autoradiography distribution showed the biotransformation of 
∆
8
-THC to the more potent and pharmacologically active 11-hydroxylated 
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Table 3. Mono-carboxylic acid metabolites of ∆9-THC. (1) man, (2) rhesus monkey, (3) 
mouse, (4) rat, (5) rabbit, (6) guinea pig, (7) dog, (8) microorganisms. 
 
 







                                                    
                   
metabolite in the monkey Callithrix jacchus (Just et al. 1975). The rhesus 
monkey metabolized Δ
8
-THC to various monohydroxy and dihydroxy 
metabolites. 11-hydroxy-Δ
8
-THC was the most abundant metabolite. 
Furthermore, all the side-chain hydroxy metabolites except 5'-hydroxy- Δ
8
-THC 
were identified. The total 4'-hydroxy- derivative was present in about one-third 
and 3'-hydroxy- in about one-sixth of the amount of 11-hydroxy-Δ
8
-THC.  Only 
minor amounts of 1'- and 2'-hydroxy- Δ
8
-THC were isolated (Halldin et al. 
1979, Widman et al. 1979).  
No    R1     R2   Species          References 
   1 2 3 4 5 6 7 8  
20 COOH C5H11 + + + + + + + - (BenZvi and Burstein 1974, Halldin et 
al. 1982c, Harvey and Paton 1976, 
Harvey et al. 1978b, Harvey et al. 
1980a, Kanter and Hollister 1978, 
Nordqvist et al. 1979a) 
21 CH3 COOH - - - - - + - - (Harvey et al. 1980a) 
22 CH3 CH2COOH - - - - - + - - (Harvey et al. 1978b, Harvey et al. 
1980a) 
23 CH3 C2H2COOH + + + - - + - + (Halldin et al. 1982b, Harvey et al. 
1978b, Harvey et al. 1980a, Nordqvist 
et al. 1979a, Robertson et al. 1978a) 
24 CH3 C3H6COOH - - - - - + - - (Harvey et al. 1978b, Harvey et al. 
1980a) 




Several mono-, di- and trihydroxy derivatives were formed by in vivo liver 
metabolism of ∆
9
-THC by guinea pigs. The 11-; 8α-; 8β-; 1’-; 2’- and 3’- were 
the monohydroxy derivatives (Table 1, compound 1,2 ,3 4, 5, 6), 8α,11-; 8β,11-; 
2,11-; and 3,11-dihydroxy derivatives (Table 2, compound 9, 10, 12, 13), 
2,8α,11- and 3,8α,11- were major trihydroxy derivatives (Table 2, compound 
18) (Harvey et al. 1978b). Guinea pigs also produced large amounts of the 
monocarboyxlic acids (Table 3, compound 20, 21, 22, 23, 24), substituted side-
chain carboxylic acid (Table 4, compound 32), mono- and dihydroxy- 
derivatives of ∆
9
-THC-11-oic acid (Table 5, compound 41, 42, 43, 44). The 
major metabolic pathways involved were allylic and aliphatic hydroxylations, 
oxidation of alcohols to ketones and acids, β oxidative degradation of the pentyl 
side chain and conjugation with glucuronic acid (Harvey et al. 1978a, Harvey et 
al. 1980a).  
Twenty-nine metabolites were reported in a study of ∆
8
-THC metabolism by 
guinea pigs. The 1'-hydroxy- and 4'-oxo-Δ
8
-THC-11-oic acid were new 
metabolites with other metabolites having β-oxidation at the side chain (Harvey 





-THC which were further converted into 7-oxo-∆
8
-THC but 
with different mechanisms in both cases (Narimatsu et al. 1988).  
Isolated perfused dog lung metabolized ∆
9
-THC into 3'-hydroxy- and 4'-
hydroxy- derivatives (Table 1, compound 6, 7) as the major metabolites, 
whereas small amounts of  8α- and 8β-hydroxy-∆
9
-THC (Table 1, compound 2, 
3) were also produced which are predominant metabolites identified from in 
vitro dog liver microsomal metabolism of ∆
9
-THC (Widman et al. 1975a). 
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Table 4. Substituted side-chain carboxylic acid metabolites of ∆9-THC (1) man, (2) 
rhesus monkey, (3) mouse, (4) rat, (5) rabbit, (6) guinea pig, (7) dog, (8) 
microorganisms. 
              Species References 
No    Side-    
chain 
Substituents 1 2 3 4 5 6 7 8  
26      COOH 11-OH, 8α-OH, 
8β-OH, 8β, 11-
di-OH 
− − − − + − − − (Nordqvist et al. 1979a)  
27     COOH 9-COOH + − − − + − − − (Halldin et al. 1982a, 
Nordqvist et al. 1979a) 
28   CH2COOH 11-OH + − − − − − − − (Halldin  et al. 1982b)  
    29  CH2COOH 8β-OH + − − − + − − − (Halldin  et al. 1982b, 
Nordqvist et al. 1979a, 
Nordqvist et al. 1979b) 
30  CH2COOH 9-COOH + − − − − − − − ( Halldin et al. 1982a)  
31  C2H4COOH 11-OH + − − − + − − − (Halldin et al. 1982b, 
Nordqvist et al. 1979b)  
32  C2H4COOH 8β-OH + − − − + + − − (Halldin et al. 1982b, 
Harvey et al. 1980a, 
Nordqvist et al. 1979a, 
Nordqvist et al. 1979b) 
33  C2H4COOH 8β, 11-di- OH −  − − − + − − − (Nordqvist et al. 1979a) 
34  C2H4COOH 



















(Halldin et al. 1982a, 
Nordqvist et al. 1979a, 
Nordqvist et al. 1974)  
(Halldin et al. 1982a, 
Nordqvist et al. 1974)  
36  C3H6COOH 8β-OH + − − − − − − − (Halldin et al. 1982b) 
37  C3H6COOH 9-COOH + − − − − − − −  (Halldin et al. 1982a)  
38C4H8COOH  9-COOH − − − − + − − − (Nordqvist et al. 1979a,     
Nordqvist et al. 1979b) 
39  CH=CH-  
COOH 
9-COOH + − − − + − − −  (Halldin et al. 1982a, 
Nordqvist M. et al. 1979a) 





+ − − − − − − − (Halldin et al. 1982b)  
 
Metabolism of THC in mice and rat 








Table 5. Hydroxy and dihydroxy derivatives of ∆9-tetrahydrocannabinol-11-oic acid. 
(1) man, (2) rhesus monkey, (3) mouse, (4) rat, (5) rabbit, (6) guinea pig, (7) dog, (8) 
microorganisms  
 Species References 
No   Position 
of OH 
1 2 3 4 5 6 7 8  
41     8α-OH − − + + −   + − −  (Harvey and Paton 1976, Harvey et al. 1978b, Harvey 
et al. 1980a)  
42     1‘-OH + − − − + + − − (Burstein et al. 1972, Halldin et al. 1982b, Harvey et 
al. 1980a) 
43     2‘-OH − − + + + + − −  (Burstein et al. 1972, Halldin et al. 1982b, Harvey and 
Paton 1976,   Harvey et al. 1978b, Harvey et al. 1980a, 
Nordqvist et al. 1979b) 
44     3‘, 4‘-di-
OH 
− − + + + + − − (Halldin et al. 1982b, Harvey and Paton 1976, Harvey 
et al. 1978b, Harvey et al. 1980a, Nordqvist et al. 
1979b) 
45    2‘,8α-, 3‘ 
,8α-, 4‘ 
,8α-di-OH 
− − + + − − − − (Harvey and Paton 1976, Harvey and Paton 1978, 
Harvey et al. 1978b) 
 
Table 6. Mono- and di-hydroxy derivatives of 8-oxo-∆9-tetrahydrocannabinol. (1) man, 
(2)rhesus monkey, (3) mouse, (4) rat, (5) rabbit, (6) guinea pig, (7) dog, (8) 
microorganisms.  
 Species References 
No  Position of OH 1 2 3 4 5 6 7 8  
    46  7-, 2‘-, 3‘-OH − + − − − + − −  (Harvey et al. 1977, Harvey et al. 1978b, 
Harvey et al. 1980a)  
47   4`-OH − − − − − + − +  (Binder 1976, Harvey et al. 1980a) 
48   2‘, 11-, 3‘, 11-, 4‘, 
11-di-OH. 
− − + − − − − − (Harvey and Paton 1978, Harvey et al. 1977, 
Harvey et al. 1978b)  
 
male mice (Charles River CD-1) to predict metabolic pathways and to find new 














-THCO-11-oic acid respectively. Sixteen 
metabolites were identified from n-hexyl-∆
9
-THC (Fig. 3d) and eleven from n-
hexyl-∆
8





-THCV) (Fig. 3d) and ∆
8
-





-THCV). The major biotransformation pathway led 
to the production of 11-hydroxy-tetrahydrocannabivarin and their further 
oxidation to carboxylic acid metabolites, other metabolites were mainly the 
hydroxy derivatives of these compounds (Brown and Harvey 1988c). 




-THC were also studied in mice. 
Hydroxylation at the allylic 11-position followed by oxidation to the carboxylic 
acid was found to be an important metabolic pathway (Harvey 1990). Little 
oxidative degradation of the pentyl side chain was found for 2'-hydroxy-∆
9
-
THC (Table 1, compound 5) but abundant metabolism occurred by oxidative 






-THC (Table 1, 
compound 6, 7) (Harvey 1989).  







-THC into a number of metabolites containing 1-3 additional groups 
at positions 2'; 3'; 4'; 8α; 8β and 11 with the only difference that ∆
11
-THC did 
not undergo allylic hydroxylation at position 11. In vivo liver metabolites of ∆
9
-
THC were extracted from rats. The 11-; 8α-; 8β-  and 3
’
- (Table 1, compound 1, 
2, 3 and 6) were the monohydroxy-, 8α,11-; 8β,11- and 3’,11- (Table 2, 
compound 9, 10, 13 ) were the  major dihydroxy- derivatives (Harvey et al. 
1978b). Rat liver microsomes transformed ∆
9
-THC into 11-oxo- (Fig. 3e) and 
further reduction of this derivative produced 11-hydroxy-∆
9
-THC (Table 1, 
compound 1) (BenZvi and Burstein 1974, Burstein and Kupfer 1971a). Rat 
lever homogenates led to the formation of 11-hydroxy- (Table 1, compound 1) 
(Burstein and Kupfer 1971b) and 8α,11-dihydroxy-∆
9
-THC (Table 2, compound 
9) (Burstein and Kupfer 1971a, Wall 1971, Wall et al. 1970). 
Rat liver incubation of ∆
8
-THC produced 11-hydroxy-; 7α,11- and 7β,11-
dihydroxy-∆
8
-THC (Wall 1971). Purified cytochrome P450 isozymes from rat 








-THC-11-oic acid (Watanabe et al. 1991). Sex related differences 
were observed in the oxidative metabolism of ∆
9
-THC between male and 
female rats. Liver microsomes of male rats biotransformed ∆
9
-THC into various 
metabolites unlike female rats in which it was mainly oxidized selectively to 11-
hydroxy-∆
9
-THC (Table 1, compound 1) (Burstein and Kupfer 1971a, 
Narimatsu et al. 1991). 
Biotransformation of THC in mammalian cells shows that cytochrome P450 
enzymes play an important role in the hydroxylation of THC. THC undergoes 
allylic hydroxylation at C-11 to form 11-hydroxy-THC which is the most 
common metabolite in almost every species studied. Allylic hydroxylation is 
also common at position 8 to give 8α- and 8β-hydroxy-THC. Other than allylic 
hydroxylations there are a number of monohydroxy and dihydroxy metabolites 
formed, being hydroxylated at all the positions of the alkane side chain of THC.
 
There is however considerable species variation in the position of substitution. 
In addition to monohydroxy and dihydroxy, some polyhydroxylated metabolites 










 while  the   monkey also formed minor amounts of metabolites having 




. The major metabolic pathway of THC (Fig. 
4) after monohydroxy metabolism is further oxidation to either a carbonyl 
compound or, in the case of the primary alcohols to a carboxylic acid, followed 
by glucuronidation of the acid. Following this biotransformation pathway there 
are a number of THC acids which are formed in man, rats, rabbits and guinea 
pigs where the acids link with glucuronide and become the major urinary 
excretion product.  
  


























Figure 4: Metabolic pathway of ∆9-THC 
 
Biotransformation of Cannabidiol 
Biotransformation of cannabidiol (CBD) has extensively been studied in mice 
and rats. Fourteen metabolites were isolated from the liver of mice after the 
administration of CBD. The most significant biotransformation step was 
glucoronide conjugation and to a lesser extent CBD-11-oic-acid was formed 
(Martin et al. 1977). Eight monohydroxy (Martin et al. 1976b) and ten 






(Martin et al. 1976a), in both cases mainly 11-hydroxylation was formed with 
further hydroxylation at C-4 of the side chain.  Over fifty metabolites of CBD 
were identified with considerable species variation in dog, rat and human urine. 
Thirty three metabolites were identified from the urine of dystonic patients 
treated with CBD. The major metabolic pathway was the hydroxylation and 
oxidation at C-11 and further hydroxylation in the pentyl and propyl groups 
produced 1'-; 2'-; 3'; 4'- and 10-hydroxy derivatives of CBD-11-oic acid. Acids 
were formed by β-oxidation and further biotransformations from the pentyl 
side-chain resulted in the formation of the oxidized metabolite CBD-11-oic acid 
(Harvey and Mechoulam 1990). In dog unusual glucoside conjugates were 




-hydroxy- and 8-oxo-CBD. Other metabolites in 
all three species were mainly acids. Side-chain hydroxylated derivatives of 
CBD-11-oic acid were abundant in human urine (Harvey et al. 1991). CBD 
followed almost the same pattern of biotransformation as observed in 
Tetrahydrocannabinol, with several variations in pathways caused by different 
species. The monohydroxylation of the side chain and also at position 11 and 8 
found in CBD is quite similar to THC. Dihydroxy compounds are also reported 
but unlike THC no trihydroxy metabolites are found in any species treated with 
CBD.  A large number of metabolites are formed by β-oxidation of the side 
chain and Glucoronidation of CBD.  
Biotransformation of Cannabinol 
Cannabinol was metabolized by rat liver into side chain hydroxylated 
compounds: the 2'-; 3'-; 4'- and 5'-hydroxy were isolated as minor metabolites 
and 11-hydroxy-CBN was formed as the major metabolite (Widman et al. 
1975b).  Cannabinol-11-oic acid was found as a major compound from rat 
feces (Yisak et al. 1977). The administration of 
14
C-labeled cannabinol to rats 
resulted in mono- and dihydroxy metabolites.  The monohydroxy 11- and 4'-
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,11-dihydroxycannabinol were the most abundant 
compounds (Fonseka and Widman 1977, Yisak et al. 1977).  
In rabbits, 4'-hydroxy-CBN was found as a major compound together with 
smaller amounts of 5'- and 3'-hydroxy-CBN (Widman et al. 1975b). In mice, 
the 11-position and the side chain of cannabinol was hydroxylated followed by 
further oxidation to acidic metabolites (Burstein and Varanelli 1975). 
Biotransformation of CBN also follows the same pattern like other 
cannabinoids but unlike other cannabinoids allylic hydroxylation of the terpene 
ring is absent in the metabolism of CBN. The 11-hydroxylation is the major 
metabolic route and further oxidation of this monohydroxy compound produces 
a common acidic metabolite, CBN-11-oic acid. 
 Biotransformation of cannabinoids by fungi and bacteria 
Robertson et al. (1978a, 1978b) screened more than 100 species of fungi and 
bacteria to investigate microbial transformations of the four common 





racemosum and Mycobacterium rhodochrous partially degraded the n-pentyl 
side chain of all these four compounds. Carboxylic acid and alcohol side chain 
derivatives were found to be the major metabolites. Among side chain 
derivatives, the 4
’
-hydroxy- metabolites were the most abundant compounds in 




-THC by Syncephalastrum 
racemosum (Robertson and Lyle 1975). 
Δ
8
-Tetrahydrocannabinol was hydroxylated at the ring system and at the side 
chain by fermentation with Pellicularia filamentosa, Streptomyces lavendulae 
or P. filamentosa and yielded the compounds 7β,3'- and 7β,4'-dihydroxy-Δ
8
-






-THC  and 4'-hydroxy-7-oxo-Δ8-THC (Vidic et al. 
1976).   
Binder and Meisenberg (1978) indentified 51 fungal and bacterial strains which 
actively transformed Δ
9
-THC into 11-; 8α-; 8β-; 3’- and 4’-hydroxy- (Table 1, 




-THC (Table 2, compound 14). 





6, compound 47) (Binder 1976).       
Binder and Popp (1980) further studied the metabolic transformations of 
9
-
THC by using cultures of Fusarium nivale, Gibberella fujikuroi (Ascomycetes) 
and Thamnidium elegans (Phycomycetes). A number of metabolites were 
isolated from these species after which they were partly purified and their 
structures elucidated by combined gas chromatography/mass spectrometry. 
Thamnidium elegans formed 11-; 8α-; 8β-; and 1
’
-hydroxy- (Table 1, compound 




-THC (Table 2, compound 16). Fusarium 
nivale and Gibberella fujikuroi both converted 
9









-THC (Table 1, compound 5, 6, 7). These results show 
that there are two different enzyme systems capable of hydroxylating the 
substrate. System 1, which is common to the “Fusarium” type and 







 of cannabinoids. In addition to this ‘aliphatic hydroxylase’ 
Thamnidium elegans posseses an ‘allylic hydroxylase’ capable of hydroxylating  
9
-THC in positions  1
’
, 8 and 11.  
Microorganisms show similarities with mammalian hydroxylation of 
cannabinoids. Cannabinoids undergo allylic hydroxylation at C-11 to form 11-
hydroxy- derivatives. Allylic hydroxylation is also seen at position 8 to give 8α- 
and 8β-hydroxy derivatives but unlike mammals, hydroxylation has also been 
found at position 7 (only found in guinea pig in mammals) and further oxidation 
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to form a carbonyl compound. In microorganisms, side chain degradation is 
found as one of the major metabolic pathways of cannabinoids. Side chain 
hydroxyl and carboxyl substitution is also common; hydroxylation is more 






with their corresponding dihydroxy metabolites. 
Trihydroxy derivatives of naturally occurring cannabinoids are not found in 
bacteria or fungi. Side chain acid derivatives are present but carboxylation of 
the monoterpene moiety and glucoronidation is not reported. 
Plant biotransformation of cannabinoids 
Cannabielsoin (CBE) and its diastereoisomers have been isolated from the 
suspension cultures of C. sativa, Saccharum officinarum and tissue culture of C. 
sativa, after the administration of cannabidiol (Braemer and Paris 1987, Tanaka 
et al. 1997). ∆
9
-THC was converted into cannabicoumaronon by a cell 
suspension culture of C. sativa (Braemer and Paris 1987). Tissue culture of 
Pinelli ternatata transformed ∆
8





-O-β-D-Glucopyranoside (Tanaka et al. 1997) and CBN-
2
’
-O-β-D-Glucopyranoside, respectively (Tanaka et al. 1993). 
Discussion and conclusions  
Despite having useful psychomimetic and pharmacological activities, research 
into cannabis has been mainly focused on its use as a recreational drug and the 
subsequent legal aspects controlling the possession of this material. Some of 
this research has been conducted on the metabolism of cannabinoids in 
mammalian systems, leading to a better understanding of their 
pharmacodynamics and pharmacokinetics. A large library of THC isomers and 
their derivatives have been developed by using mammalian cytochrome P450 
systems, which is a successful approach to finding metabolic pathways but little 
is known about the activity and interaction of these metabolites with the CB1 




Perhaps the industrial scale production of potential compounds by means of 
mammalian cells or tissue is an expensive tool and thus an obstacle to develop 
cannabinoid based drugs. There are a number of other sources which can be 
used to enlarge the library of active metabolites obtained from the 
transformation of cannabinoids. Cannabinoids have been successfully 
transformed by fungal and bacterial strains, while there are only a few reports 
on the biotransformation with plant cell cultures. Microorganisms mimic some 
of the mammalian biotransformation pathways and their enzyme systems have 
great potential to produce improved or novel compounds in large quantities 
keeping production at a low cost.  
Bacterial cytochrome P450 (monooxygenases) enzymes have the ability to 
hydroxylate exogenous and endogenous compounds at different positions. In 
the case of cannabinoid transformations, hydroxylation is likely to produce 
more polar cannabinoids which might be more suitable for medicinal use than 
parent compounds, which generally tend to accumulate in fat tissues. The 
significant role of the alkane side chain has been reported in the 
pharmacological action of THC (Billy et al. 1995) and further oxidation may 
change the chemistry of the side chain and lead to enhanced or modified activity 
of the compound. By taking into account these findings, we used alkane 
degrading bacterial strains for the transformation of ∆
9
-THC and found eight 
major metabolites produced in mg scale. All these transformations were limited 
to the side chain and included two carboxylic acid derivatives formed by 





THC (Rashidi et al. 2009). Numbers of new lead candidates are possible to 
obtain by using the enzymatic systems of bacterial, yeast and plant cells in 
cannabinoid transformation in combination with advanced chromatographic and 
analytical techniques. 
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 There are more than 72 known cannabinoids but few reports on the metabolism 
or transformation of any other natural cannabinoid, except ∆
9
-THC, CBN and 
CBD. Low availability of most of the cannabinoids limits the study of their 
pharmacological properties. There is a demand for non-psychoactive 
cannabinoids and their metabolites produced after biotransformation, as this 
might be a source of new compounds with interesting pharmacological profiles. 
Further studies with different microorganisms and a diverse range of 
cannabinoids is thus of great interest. New cannabinoid derivatives devoid of 
the psycho activity with only the desired profile of pharmacological activity are 
of great interest to the scientific community.   
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The microbial biotransformation of Δ
9
–tetrahydrocannabinol was investigated 
using a collection of 206 alkane-degrading strains. 15% of these strains, mainly 
Gram-positive strains from the genera Rhodococcus, Mycobacterium, Gordonia, 
and Dietzia yielded more polar derivatives. Eight derivatives were produced on 
a mg scale, isolated, purified, and their chemical structures were elucidated with 
the use of LC-MS, 
1




H COSY and HMBC). All 
eight biotransformation products possessed modified alkyl chains, with 
hydroxy, carboxy and ester functionalities. In a number of strains, β-oxidation 
of the initially formed C5 carboxylic acid led to the formation of a carboxylic 






-THC) is the decarboxylated product of the 
corresponding Δ
9
-THC-acid, the major cannabinoid present in the cannabis 
plant (Cannabis sativa L., Cannabaceae). This compound is officially registered 
as a drug for the stimulation of appetite and antiemesis in patients under 
chemotherapy and HIV therapy regimes. Other biological activities ascribed to 
this compound include lowering of intraocular pressure in glaucoma, as 
analgesic for muscle relaxation, immunosuppression, sedation, bronchodilation, 
and neuroprotection (Grotenhermen 2003). 
Δ 
9
-Tetrahydrocannabinol and many of its derivatives are highly lipophilic and 
poorly water-soluble with a logPo/w > 4.5 for Δ
9
-THC (Thomas et al. 1990). 
Calculations of the n-octanol/water partition coefficient (Ko/w) of Δ
9
-THC at 
neutral pH, vary between 6000 using the shake-flask method (Mechoulam 
1982), and 9.44×106 by reverse-phase HPLC estimation (Thomas et al. 1990). 
The poor water solubility and high lipophilicity of cannabinoids cause their 
absorption across the lipid bi-layer membranes and fast elimination from blood 
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circulation. In terms of the 'Lipinsky rule of 5' (Lipinski 2000), the high 
lipophilicity of cannabinoids is hindering the further development of these 
compounds into large scale pharmaceutical products. 
To generate more water-soluble analogues, one can either apply de novo 
chemical synthesis, or modify naturally occurring cannabinoids, e.g. by 
introducing hydroxy, carbonyl or carboxy groups.  Chemical hydroxylation of 
compounds such as cannabinoids is difficult (Δ
9
-THC is converted into Δ
8
-THC 
under mild conditions), microbial biotransformation of cannabinoids is 
potentially a more fruitful option to achieve this goal.   
So far, studies on biotransformation of Δ
9
-THC were mainly focused on fungi, 
which lead to the formation of a number of mono- and dihydroxylated 
derivatives. Previous reports on the biotransformation of cannabinoids by various 
microorganisms are summarized in Table 1. 
The aim of the present study was to test bacterial strains capable of 
transforming Δ
9
-THC to new products (with potentially better pharmaceutical 
characteristics) at a higher yield and specificity than previously found for fungal 
strains. For this purpose, we have chosen to use a collection of alkane-degrading 
strains, since it was shown in previous studies (Duetz et al. 2001, Smits et al. 
2002, Beilen et al. 2005) that alkane oxygenases often display a broad substrate 
range. Production of novel cannabinoid derivatives that might have interesting 
pharmacological activities was another objective of this project. 
Materials and methods 
Bacterial strains and growth conditions: A total of 206 alkane-degrading 
strains (mainly isolated from soil and surface water, see (Beilen et al. 2005) 
were screened. An optimized Evans mineral medium according to (Duetz et al. 




Table 1. Previous biotransformation experiments conducted using various 
microorganims to transform cannabinoids 
Cannabinoid(s)         Microorganism(s) used                       No. of transformed      Reference 
                                                                                                            Products 
Δ9-THC                 Cunninghamella blakesleeana                                 6               (Binder 1976) 
Δ8-THC                 Pellicularia filamentosa                                          4          (Vidic et al. 1976)              
Δ8-THC                 Streptomyces lavendulae                                         4           (Vidic et al. 1976) 
Δ6a, 10a-THC          400 cultures (Soil microorganisms)               various        (Abbott et al. 1977) 
Nabilone             400 cultures (Soil microorganisms)                various         (Abbott et al. 1977) 
Δ6a, 10a-THC         358 cultures containing bacteria,                             3         (Fukuda et el. 1977)    
                             actinomycetes, and molds 
 
Δ9-THC, Δ8-THC, Syncephalastrum racemosum,                       various    (Robertson et al. 1978) 
CBD,  CBN            Mycobacterium rhodochrous 
 
Δ9-THC                Chaetomium globosum                                            3       (Christie et al.  1978) 
Δ9-THC                51 fungal strains                                                     8 (Binder and Miesenber 1978) 
Nabilone               Microbes                                                          various        (Archer et al. 1979) 
Δ9-THC                 Fusarium nivale, Gibberella fujikuroi                  8       (Binder and pop 1980) 
                              and Thamnidium elegans 
   
sources was used throughout this study. All cultures were grown aerobically at 
30 
o
C. To grow bacteria on agar-based media, pre-warmed Evans mineral 
medium (E4T) was mixed with a molten 4 % agar no.2 solution (1:1 v/v) and 
dispensed in either Petri dishes or microtiter plates. For growth on n-alkanes, 
Petri dishes containing E4T medium were incubated at 30 
o
C with n-alkanes 
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supplied through the vapor phase by placing an open Erlenmeyer flask with the 
mixture of alkanes in a sealed container holding the Petri dishes.     
Miniaturized screening: The alkane degrading bacteria were screened using a 
microtiter based technology platform as described before (Duetz et al. 2000, 
Beilen et al. 2005). Briefly, multiple strains stored in one 96-well microtiter 
plate at -80°C were sampled simultaneously without thawing the bulk cultures 
by using a spring-loaded 96-pin replicator (Kühner, Basel, Switzerland) as 
previously described (Duetz et al. 2000) and were transferred to a regular sterile 
polystyrene microtiter plate (type 3072; Costar, Cambridge, Mass.). Each well 
(working volume, 350 μl) contained 180 μl of a solidified mineral medium agar 
(2% [wt/vol]) without a carbon source. The inoculated microtiter plate was 
placed in a desiccator together with a beaker of water and a 50-ml beaker 
containing 10 ml of a 1:1:1:1:1 (vol/vol/vol/vol/vol) mixture of hexane, octane, 
decane, dodecane, and hexadecane. The lid on top was kept 2 mm from the 
wells in order to allow for a sufficient supply of gaseous alkanes to the wells. 
After 7 days of growth at the ambient temperature (30°C), the cell mass that 
developed on the agar surface was harvested as follows. First, 110 μl of 
potassium phosphate buffer (50 mM, pH 7.0) was added to each well. Repeated 
lateral movement of the spring-loaded replicator in the wells resulted in 
suspension of a large part of the cell mass. The suspensions were subsequently 
transferred by using a 12-channel multipipette and wide-orifice tips to a 
microtiter plate with 0.5-ml conical wells (Maxi-plaque; Polylabo, Geneva, 
Switzerland). The microtiter plate was centrifuged for 15 min at 4,000 rpm in an 
Eppendorf type 5403 centrifuge. After disposal of the supernatant, the cells 
were resuspended in 100 μl of a buffer (50 mM potassium phosphate buffer [pH 
7.0]) by repeated filling and emptying of wide-orifice pipette tips by using a 12-
channel multipipette. Subsequently, 2 µL substrate (20 g/L Δ
9
-THC in 




was added to each well and the wells were closed by using a sandwich cover 
consisting of a pierced layer of soft silicone combined with a rigid 
polypropylene plate. The microtiter plate was incubated for 6h at 30 
o
C with 
orbital shaking at 300 rpm and an amplitude of 50 mm. To extract the 
metabolites, 50 µL of chloroform was added to each well after incubation. The 
microtiter plate’s contents were transferred into 1.5 ml tubes and then 
centrifuged for 10 min at 12,000 ×g. The chloroform layer was transferred to 
another 1.5 ml tube and air-dried. The residue was re-dissolved in MeOH and 
used for analysis by HPLC and LC-MS.   
Large scale Biotransformation: Three selected alkane degrading bacteria 
(ENZHR1, ENZHR3 and ENZHR5) were cultured in 500 ml flasks containing 
100 ml E4T medium aerobically at 30 
o
C. A mixture of n-alkanes was supplied 
through the vapor phase using a small plastic container attached to the flask’s 
cap, as described above. The flasks were incubated for 18-24h at 30 
o
C with 
orbital shaking at 300 rpm and an amplitude of 50 mm. Then 2 ml of substrate 
(20 g/L Δ
9
-THC in methanol) was added to each flask and incubated for a 
further 24 hrs. Metabolites were produced on a 1-10 mg scale and were 
extracted as described above. In order to increase the extraction efficiency of 
acid derivatives, hydrochloric acid (HCl) was added to aqueous phase before 
extraction. 
Purification of metabolites: All transformed metabolites were purified with a 
semi-preparative Agilent 1200 HPLC. Various ratios of aqueous methanol were 
employed to purify the different products. The column employed was a RP18 
Phenomenex (250X10mm, 5µm). The yields of all metabolites were in the 1-10 
mg range. 
HPLC-APCI-MS Analysis: Analysis was performed by using a high-
performance liquid chromatography (Agilent 1100 series, Hannover, Germany) 
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equipped with a diode array detector, and a mass detector in series. Solvent 1 
(methanol containing 0.1% formic acid) and 2 (water containing 0.1% formic 
acid) were used at a 70:30 (v/v) ratio for 7 min isocratically. This was followed 
by a gradient to 100% solvent 1 over a period of 6 min. After 1 min the mobile 
phase was returned to the starting conditions and left to re-equilibrate for a 
further 3 min. (total run time of 17 min).  A Macherey-Nagel (Duren, Germany) 
Nucleosil C18 column (70 mm length, 3µm internal diameter, 5µm particle size) 
equipped with an 8 mm-long pre-column of the same material was used to 
separate the components. The settings of the mass spectrometer (MS) were as 
follows: APCI mode; positive ionization; fragmentor voltage 100 and 240 V; 
gas temperature, 350 
o
C; vaporizer temperature, 400 
o
C; drying gas (N2) flow 
rate, 4 liters min
–1
; nebulizer pressure, 45 psig (lb/in); capillary voltage, 4000 V; 
corona current, 4.0 µA.   
Determination of the maximal solubility of metabolites: 20 µL of 10 mM of 
each sample in methanol was dried in eppendorf tubes.  20 µL of 50 mM 
phosphate buffer pH 7.0 were added to each eppendorf, vortexed for 5 minutes 
and were left over night. After centrifugation for 10 minutes in 2000 g in room 
temperature, 5 µL of supernatant was diluted 20 times in methanol and was 
analysed by HPLC under the same condition as described above.  
NMR: The purified compounds after evaporation of MeOH were re-dissolved 
in CD3OD and 
1
H-NMR (400 MHz) spectra were recorded by a Bruker model 
AV-400 NMR spectrometer with reference to residual solvent as standard.  
Results 
Screening. To identify appropriate bacterial strains for the bioconversion of 
cannabinoids to more polar derivatives, we screened 206 (largely unidentified) 
alkane-degrading strains grown with a mixture of alkanes as their sole source of 




16S RNA sequencing. Formation of more polar compounds was observed for 
76 strains, of which 44 strains converted more than 50% of substrate after 6 
hours incubation at a cell density of approximately 5 g dry wt / L.  In seventy of 
the strains capable of converting Δ
9
-THC into more polar derivatives, only 
compounds [3] and/or [4], (Table 2) were formed in significant amounts.  In 
only 6 of the strains other compounds were formed. In total eight different 
metabolites were identified (based on relative retention time, UV spectra, and 
mass spectra). The proposed structures (based on MS and NMR data; see 
further below) are given in (Table 2). 
Metabolite [1] was the most polar derivative identified during the screening 
procedure and it was produced only by Gordonia sp ENZHR5 in relatively 
small quantities. Metabolite [2] was the second most polar derivative and was 
produced by only 4 of the screened strains, in a very low yield. The molecular 
mass of 347 [M+H], and the absence of any significant change in the UV 
spectra in comparison to Δ
9
-THC suggested modification of the alkyl moiety. 
Metabolites [3] and [4] were the most abundant and were produced by all 76 
strains, though in varying ratios. This ratio was observed to be not only strain-
dependent, but was also influenced by the concentration of substrate, cell 
density and incubation time. In general, higher cell densities and longer 
incubation times resulted in increasing concentrations of compound [3], 
suggesting compound [3] was a product of through-conversion of [4] to [3]. 
Metabolite [5] was produced by three strains, all of them also capable of 
production of metabolite [2]. A steady decrease in the concentration of 
metabolite [5] and an increase of metabolite [2] with a prolonged incubation 
time suggests that metabolite [5] is a precursor of metabolite [2]. Metabolite [6] 
was produced only by microorganisms capable of production of metabolites [2] 
and [5] in a time-dependent manner and a very low yield. Metabolites [7] and 
[8] were formed by only 1 of the screened strains. 
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After preliminary analysis of the results, we focused on three strains that 
biotransformed Δ
9
-THC at relatively high yields, and which covered all 
produced derivatives based on retention time of peaks and the molecular mass 
as determined by the LC-MS analysis. These strains were a Dietzia sp ENZHR1 
yielding one major metabolite, a Mycobacterium sp ENZHR3 and a Gordonia 
sp ENZHR5, both producing a mixture of derivatives.  
Structure elucidation. The chemical structures of metabolites [1-8] were 






H COSY and HMBC. The 
1
H-
NMR spectrum of all eight metabolites were in accordance with Δ
9
-THC with 
regard to the signals due to two angular methyl groups [3H each, s at δ 1.41, C6 
β methyl and δ 1.09, C6 α methyl], and three aromatic and olefinic protons (1H, 
q, J= 1.6 Hz, at δ 6.31, H-10; 1H, d, J=1.6 Hz at δ 6.14, H-4; 1H, d, J= 1.6 Hz 
at δ 6.06, H-2) (Choi et al. 2004). The changes were mostly limited to the 
signals representing protons in the alkyl side chain. The 
1
H-NMR chemical 
shifts of the main signals of the metabolites and Δ
 9
-THC are shown in Table 3. 
On the basis of these proton NMR data, MS spectra and UV spectra, we 
propose compounds [1-8] to have the chemical structures as mentioned below, 
with the following argumentation: 
3'-hydroxy-Δ
9
-THC-5’-oic acid [1]:  
1
H NMR (CD3OD, 400MHz). The 
signals representing H-5’ (tertiary methyl group at δ 0.87) disappeared and H-4’ 
(2H, m, at δ 1.29) shifted up-field to δ 2.32 ppm. The signal representing H-3’ 
(2H, m, at δ 1.29) could not be detected; instead a new single proton signal at δ 
3.92 ppm was observed. The aromatic protons of H-2 and H-4 showed a slightly 
downfield shift from δ 6.06 and δ 6.14 to δ 6.09 and δ 6.16, respectively. The 
signal of H-2’ (2H, m at δ 1.55) shifted to δ 1.70 (2H, m) and the signals 
representing the two H-1’ (2H, td at δ 2.42 in (Δ
9
-THC) divided into two signals 




Table 2: The proposed structures for the Δ9-THC derivatives formed in the present 
study with their respective differences in physicochemical properties  
Compound     
No 
  Chemical   Name rRT               




  Proposed structure 
 Δ
9-THC 1.000 210,280 314               NA 
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Δ 9-THC-4’,5’-bis, nor-
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1’,2’-dehydro- Δ 9-THC-
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proton each. APCI-MS m/z 361 [M]
+
 (100), 343 (54), 325 (11). Based on the 




H cosy data (data not provided), we 
propose the structure as given in Table 2 for this compound. 
1'-hydroxy-Δ
9
-THC-4’,5’-bis, nor-3’-oic acid-methyl ester [2]. 
1
H NMR 
(CD3OD, 400MHz). The signals representing H-5’ (tertiary methyl group at δ 
0.87), H-4’ (2H, m, at δ 1.29) and H-3’ (2H, m, at δ 1.29) was not observed. The 
aromatic protons of H-2 and H-4 showed a slightly downfield shift from δ 6.06 
and δ 6.14 to δ 6.25 and δ 6.35 respectively. The signal of H-2’ (2H, m at δ 
1.55) shifted to δ 2.67 (1H, dd) and δ 2.61 (1H, dd); the signal representing H-
1’ (2H, td at δ 2.42 in Δ
9
-THC) showed a strong downfield shift to δ 4.80 with 
an intensity of one proton. Presence of a new methyl ester signal at δ 3.66 was 
confirmed by HMBC which shows a long range coupling of a new signal 
representing a methyl ester group with carbonyl group around 173 ppm. APCI-
MS m/z 347 [M]
+
 (10),  329 (100). Based on this information we propose the 
structure as in Table 2 for this compound.  
Δ
9
-THC-5’-oic acid [4]. 
1
H NMR (CD3OD, 400MHz). The 
1
H-NMR spectrum 
is in accordance with Δ
9
-THC as explained above but the tertiary methyl group 




4’ (2H, m, at δ 1.29, H-3’; 2H, m, at δ 1.29, H-4’) have shifted downfield to δ 
1.59 and δ 2.29 respectively. A slightly downfield shift of the signal 
representing proton H-2’ (2H, m) from δ 1.55 to δ 1.60 was observed but there 
were no significant change in the signal of H-1’ (2H, m, at δ 2.42). APCI-MS 
m/z 345 [M]
+
 (100), 327 (11). Based on the collected data, we propose that 
compound [4] is Δ
9
-THC 5’-oic acid (Table 2). 
Δ
9
-THC-4’,5’-bis, nor-3’-oic acid-methyl ester [5]. 
1
H NMR (CD3OD, 
400MHz). The 
1
H-NMR spectrum lacked the signals representing H-5’ (tertiary 
methyl group at δ 0.87) H-3’ (2H, m, at δ 1.29) and H-4’ (2H, m, at δ 1.29). A 
significant downfield shift in the signal representing proton H-2’ (2H, t) from δ 
1.55 to δ 2.58 and slight downfield shift of H-1’ (2H, td) from δ 2.42 to δ 2.74 
and appearance of a new signal (3H, s) at δ 3.68 a typical signal of methyl ester 
group, were the main changes in the 
1
H-NMR in comparison to Δ
9
-THC. Long-
range coupling of this new signal with a carbonyl group at 173 ppm in the 
HMBC spectra confirmed the presence of methyl ester substitution. APCI-MS 
m/z 331 [M]
+
  (100),  299 (70). Based on the information provided above, we 
propose the structure as given in Table 2 for compound [5].  
Δ
9
-THC-5’-oic acid-methyl ester [6].  
1
H NMR (CD3OD, 400MHz). The 
1
H-
NMR spectrum is in accordance with Δ
9
-THC as explained above and identical 
to compound [4] with only the presence of one additional signal (3H, s, at δ 
3.63 typical for a O-methyl ester (confirmed by HMBC). APCI-MS m/z 359 
[M]
+
  (100),  327 (22). Based on the collected data, we propose that compound 
[6] is Δ
9
-THC-5’-oic acid-methyl ester (Table 2). 
1’,2’-dehydro-Δ
9
-THC-4’,5’-bis, nor-3’-oic acid [7]. 
1
H NMR (CD3OD, 
400MHz). Most of the 
1
H-NMR spectrum is in accordance with Δ
9
-THC as 
described above but the tertiary methyl group at δ 0.87 representing H-5’ and 
signals representing H-3’ and 4’ (2H, m, at δ 1.29, H-3’; 2H, m, at δ 1.29, H-4’; 
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                  Table 3. 1H NMR chemical shifts (ppm) of the altered signals of new metabolites as compared to Δ9-THC. 
Chemical shifts (ppm) for compound 
        position Δ
9
-THC 1 2 3 4 5 6 7 8 
2  6.06, d    
(1.6) 




















































1’ (new signal)  2.57, m        
2’ 1.55, q 
(7.8) 
1.7, m 2.67, dd 
(15.2, 8.8) 
2.4, td  
 (7.6, ~1) 
1.6, m  2.58, td    
(6.0, ~1) 
1.6, m 7.42, d  
(16) 
7.46, d  
(16) 
2’ (new signal)   2.61, dd 
(15.2, 2.4) 
      
3’ 1.29, m 3.92, bs   1.59, m  1.59, m   
4’ 1.29, m 2.32, m   2.29, m  2.32, td 
(7.2, ~1) 
  
5’ 0.9, t (7.0)         




respectively) disappeared. A significant downfield shift observed in the signals 
representing the aromatic protons of H-2 (1H, d) and H-4 (1H, d) from δ 6.06 
and δ 6.14 to δ 6.47 and δ 6.55 respectively. Signals representing protons H-2’ 
(2H, t, at δ 1.55) and H-1’ (2H, td, at δ 2.42) changed to 1H doublets and shifted 
to 7.42 and 6.32 ppm, respectively. Significant changes in UV absorption of the 
compound suggested a further conjugation of a chromophore with the aromatic 
ring. A coupling constant of H-1 and H-2 (J=16 Hz) indicated a trans formation 
of the vicinal protons of a double bond between C-1’ and C-2’. Fig. 1 shows the 
proposed structure for compound [7] with a trans configuration of the protons at 
C-1' and C-2'. APCI-MS  m/z 315 [M]
+
  (100), 297 (15). 
 




-THC-4’,5’-bis, nor-3’-oic acid-methyl ester [8]. 
1
H NMR 
(CD3OD, 400MHz). Most of the 
1
H-NMR spectrum is in accordance with Δ
9
-
THC as described above and identical to compound 7 with only the presence of 
one additional signal (3H, s, at δ 3.68 typical for a O-methyl ester (confirmed by 
HMBC). APCI-MS  m/z 329 [M]
+
 (100),  297 (10). Table 2 shows the proposed 
structure for compound [8] with a trans configuration of protons at C-1' and C-
2'. As shown in Fig. 1, production of new metabolites in Dietzia sp ENZHR1 
was limited to [3] and [4] while the production of compound [3] yielded less 
than 5% of the total conversion based on their respective HPLC chromatogram 
areas. In Mycobacterium sp ENZHR3, compound [3] is one of the major 
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products (35-70% of total conversion based on the incubation condition) while 
compound [5] is the second most abundant metabolite. Compounds [2], [6] and 
[8] were found to be minor products. Formation of [4] is totally dependent on 
incubation conditions. Production of [5], [6] and [8] in Mycobacterium 
ENZHR3 increased in a time-dependent manner accompanied by a decreasing 
amount of [3] and [4] (Fig. 2). Gordonia sp ENZHR5 also showed a multi-
roduct pattern of production, although [1], [3] and [7] were the most abundant 
metabolites formed (Fig. 3).  
        
 





Figure 3:  Metabolites by Gordonia sp ENZHR5 during biotransformation of Δ9-THC  
Solubility studies. The physicochemical properties of the derivatives were 
found to be significantly different from those of the parent compounds. For [3] 
and [4], the water-solubility at pH 7 are up to 8.5 and 4.5 mM respectively 
which is a dramatical increase in comparison to the solubility of Δ
9
-THC and 
CBD (50 and 135 µM, respectively). Solubility of the methyl ester derivatives is 
also assumed to be improved based on their HPLC retention time in comparison 
to the parent compounds. The double bond between C-1’ and C-2’ has a 
negative effect on solubility; for example [7] has a 1.4 fold lower solubility 
compared to the saturated metabolite (6.2 mM for the dehydro metabolite). 
 




In this study, we established that a significant part (approx 37%) of a randomly-
isolated collection of bacterial alkane degraders is capable of hydroxylation and 
further modification of the pentane moiety of tetrahydrocannabinol. A total of 
eight compounds were produced on a 1-10 mg scale. Their structures were 
elucidated using MS and UV spectrometry, 
1





COSY and HMBC). 
The finding that Gram-positive alkane degraders from the CMN group 
(including Rhodococci and Mycobacteria) were overrepresented in the group of 
THC-converters possibly reflects their relatively good cell wall permeability for 
lipophilic compounds as a result of the absence of a LPS layer. The best 
producers were from the genera of Dietzia, Mycobacterium and Gordonia.  A 
similar overrepresentation of Gram-positives was observed in similar screenings 
for the bioconversion of D- and L-limonene (van Beilen et al. 2005). A possibly 
broader substrate range of the (mainly P450) alkane monooxygenases in these 
strains  may also have played a role in this finding. 
The most frequently found metabolites were [3] and [4]. Probably compound 
[4] was formed as a result of the action of an alkane monooxygenase, in 
combination with two aspecific dehydrogenases (possibly, but not necessarily 
alkanol dehydrogenases). The assumed initial product (Δ
9
-THC-5’-OH) was not 
detected in significant amounts, probably reflecting the relatively high specific 
activities of the dehydrogenases responsible for the further oxidation of the 
alcohol. Compound [3] is also a carboxylic acid, but its alkane chain is two 
methylene groups shorter. In the light of the gradual conversion of compound 
[4] to compound [3] (as was observed for a number of strains) it seems 





Other metabolites were produced by only a few screened strains and normally in 
low yields, except compounds [1] and [7] that were produced in high yields by 
Gordonia sp ENZHR5. Further work is needed to assess which enzymes are 
responsible for these conversions. 
 Formation of Δ
9
-THC derivatives with a C-3 side chain has been observed 







-THC-5’-oic acid in another study (Harvey and Leuschner 1985). 
The possible (pharmaceutical) application of the isolated derivatives is presently 
the subject of further study. The improved water solubility (8.5 and 4.5 mM for 
compounds [3] and [4]) would make them better pharmaceuticals in terms of the 
Lipinski rules. This positive effect might however be offset by changes in their 
affinities for the relevant receptors. Therefore, the isolated compounds are 
presently being tested with respect to their binding affinities for the CB1 and 
CB2 receptors.  
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The aim of this study was to test the capability of Catharanthus roseus 
suspension cultured cells for converting Δ
9
-THC into more polar derivatives. 
The transformed metabolites were analysed and isolated by HPLC. Structures of 
some new derivatives were proposed on the basis of molecular ion peaks, 
fragmentation pattern and spectroscopic data obtained from LC-MS. Δ
9
-THC 
was rapidly absorbed by Catharanthus roseus cultured cells and upon 
biotransformation new glycosylated and hydroxylated derivatives were isolated 
by preparative HPLC and identified using LC-MS molecular ion peaks, 
fragmentation patterns and spectroscopic data. In addition, cannabinol was 
detected as degradation product, including its glycosylated derivative. In the 
compound uptake efficiency, Δ
9
-THC was rapidly absorbed by Catharanthus 
roseus cell suspension cultures line CRPP.  Based on these results, it is 
concluded that Catharanthus cultured cells have great potential to transform Δ
9
-
THC into more polar derivatives and can be used for the large scale production 
of new cannabinoids, which can be a source of new compounds with interesting 
pharmacological profiles.    
Introduction 
Besides microbial and fungal cultures, plant cell cultures have also been utilized 
for biotransformation. Even though plant cell cultures most often have less 
capacities and resources to produce specific secondary metabolites compared to 
intact plants, they often retain the ability to perform all biocatalytic steps and 
are well able to efficiently transform exogenously applied substrates into 
products of interest. Moreover, it is often noted that plant cell cultures can take 
up and transform xenobiotic compounds according to metabolic pathways of 
endogenous metabolites with structural similarities, which may well lead to 
novel and valuable products with improved properties regarding stability, bio-
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activity and solubility (Ishihara et al. 2003). Some attempts have also been 
made to test the plants and plant cells for the transformation of cannabinoids 
into new chemical entities. For example, some suspension cultures of Cannabis 
sativa (C sativa) and Saccharum officinarum were used to convert cannabidiol 
to cannabeilsoin (Braemer et al. 1987, Hartsel et al. 1983) and 
tetrahydrocannabinol to cannabicoumaron (Braemer and Paris 1987).  
Catharanthus roseus cell enzyme system has been successfully used for the 
development of new compounds by the hydroxylation and glycosylation of the 
parent compound into its derivatives with enhanced water solubility. Furuya et 
al. (1992) reported the epoxidation of tabersonine into lochnericine and further 
methoxylation into lochnerinine by using a suspension culture of C. roseus.  
Catharanthus roseus cell suspension culture spiked with vanillin was able to 
convert the compound into glucovanillin (Sommer et al. 1997, Yuana et al. 
2002), vanillic acid and glucovanillic acid (Yuana et al. 2002). 
Feeding/elicitation of a C. roseus cell suspension culture with salicylic acid 
resulted in hydroxylation of this compound into 2.5-dihydroxybenzoic acid 
(gentisic acid) followed by a glycosylation of the hydroxyl group at C-5 
(Shimoda et al. 2002, Mustafa et al. 2009). Catharanthus roseus was also used 
to transform triptolide (Ning et al. 2004) and cinobufagin (Ye et al. 2003) into 
the new products 12β, 13α-dihydroxytriptonide and 3-epi-
desacetylcinobufotalin respectively. Deoxyartemisinine was obtained from a 
suspension culture of C. roseus after feeding the antimalarial compound 
artimisinine (Patel et al. 2010). The aim of the current study is to investigate the 
potential of C. roseus cultured cells for the transformation of Δ
9
-THC for 
producing more polar compounds, while maintaining pharmacological activity. 
In addition, we studied the effect of the compound on the biomass accumulation 














-THC was purified according to Hazekamp et al. (2004).  
Plant cell cultures: 
Catharanthus roseus cell suspension culture line CRPP was grown in 
Gamborg’s B5 medium (Gamborg et al. 1968) supplemented with 2% glucose 
and 1.86 mg/L naphthalene-3-acetic acid (NAA). The cells were grown in 250 
mL-Erlenmeyer flasks containing 100 mL of the medium and cultivated at 24 (± 
1)
°
C under continuous light (500-1500 lux) at 100 rpm. Subculturing the cells 
for maintenance was performed every 3 weeks by diluting the cultures 1:1 with 
fresh medium. For the experiment, 30 ml of the 3-week old cultures were 
pipetted into 50 ml fresh medium in a 250 mL-Erlenmeyer flask. 
Feeding experiments: 
For the feeding experiment 18 cultures were inoculated as described above and 
three medium flasks were maintained at similar conditions; treatments were 
performed in triplicate for all conditions at day five after subculturing, which 
corresponded to mid-exponential phase. The cell cultures received either Δ
9
-
THC (8 mg; dissolved in 0.8ml of ethanol at 24 and 48h), ethanol as solvent 
control (0.8ml) for 24 and 48h or remained untreated as non-fed control for 24 
and 48h. Subsequently cells and medium were harvested at 24 and 48 hours 
after treatment. The medium flasks were spiked with Δ
9
-THC at the same time 
and collected after 48 hours to determine effect of medium, pH and light on Δ
9
-
THC Cells were harvested by vacuum filtration using a Bűchner funnel and 
Whatman  filter paper (d=90 mm; Ref No: 10311809, Whatman GmbH, Dassel, 
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Germany) ; after initial filtration the medium was collected and cells were 
washed with 100 ml of Millipore water. The cells were transferred into 50 ml 
falcon tubes, frozen in liquid nitrogen and stored at -20 
°
C before further 
analysis. 
Extraction  
Collected cells were lyophilized and weighed. Fifty mg of cells (DW) were 
weighed into a 1,5 mL microtube and extracted with 1 ml methanol by 
vortexing (1 min) followed by ultrasonication for 15 minutes (at room 
temperature). The supernatants were collected by centrifugation (20 min at 
13,000 rpm), and extraction of the remaining cell biomass was repeated twice, 
each time using 1 ml methanol. The pooled supernatant was evaporated to 
dryness and dissolved in 1 ml of ethanol p.a for LC-MS analysis. Media were 
extracted three times with an equal volume of EtOAc (50 ml). The media 
extracts were dried with a rotary evaporator, weighed, and dissolved in 1 ml 
ethanol p.a.; 10 ul was injected for HPLC analysis. 
Hydrolysis of extracts 
Cell extracts were hydrolysed in order to release Δ
9
-THC from its glucoside 
forms and for confirmation of the glucosylated products. For this purpose, 1 mg 
cells (DW) from the Δ
9
-THC -fed cultures were weighed into 1,5 ml microtubes 
and extracted with 0.5 ml methanol combined with 0.5 ml of 6 N HCl. The 
mixture was placed in a water bath at 80
°
C for 1 h (Meuwly and Metraux 1993). 
The hydrolysed samples were extracted with 1 ml of chloroform (three times), 
the pooled chloroform fractions were dried under a nitrogen flow, re-dissolved 
in ethanol and 10 μl injected to the LC-MS system.  
HPLC Conditions 




with an autosampler, injector and a photo diode array (PDA) detector. A 
Phenomenex C18 (150 x 4.6 mm, 5μm particle size) column was used for 
chromatographic analysis. The mobile phase consisted of methanol and water, 
acidified with 25 mM of formic acid. The column was run with a gradient of 
methanol (65 to 100%) over 25 minutes.  The column was further run for 3 min 
with 100% methanol followed by re-equilibration of the column under initial 
conditions for 4 min. Flow rate was 1.0 ml/min and the UV detection was set at 
228 nm. 
Isolation of some target compounds were performed using a preparative 
Phenomenex C18 (250 x 4.6 mm, 5 µm particle size) column using an isocratic 
elution system with MetOH-water (85-15) with a run-time of 25 minutes, a 
flow-rate of 2.0 ml/min and detection at 228 nm. 
LC-MS Analyses 
LC-MS analyses for product identification were performed by using an Agilent 
1100 HPLC single-quadrupole mass-spectrometer. Instrument operation and 
data acquisition were controlled through Agilent LC/MSD Chemstation A.10.02 
software (Santa Clara,CL, United states). The HPLC system and column 
conditions were the same as mentioned above. The settings of the mass 
spectrometer (MS) were as follows: APCI mode; Positive and negative 
ionization; fragmenter voltage, 150 and 250 V; gas temperature, 350C; 
vaporizer temperature, 350 
°
C; drying gas (N2) flow rate, 5 liters min
-1
; 
nebulizer gas pressure, 35 psig (lb/in
2
); capillary voltage, 4000 V; corona 
current, 4.0 μA. Ions were detected in the range of 100-1000 u. 
Statistical analysis  
Statistical analyses were performed using GraphPad Prism for Windows 
(version 5.03) and also used to plot graphs. To analyze the impact of EtOH and 





-THC on total dry cell weight, we used one-way analysis of variance and a 
Dunnett’s Multiple comparison test with probability level of 5% as the minimal 
criterion of significance. 
Results and discussion 
Quantitative analysis of Δ
9
-THC in the media and the cells was performed in 
order to study the efficiency of uptake of this compound by the C. roseus cells 
line CRPP. The presence of a small proportion of the compound/substrate in the 
cells and only traces in the media (Figure 1A) shows the quick uptake of 
compound by the C. roseus cells. Further, the transformed products were 
released back into the media. The effect of growth conditions (temperature, 
light, humidity etc.) on the stability of Δ
9
-THC was studied by incubating the 
media spiked with Δ
9
-THC for 48 h (as negative control). The identification and 
quantification of cannabinol (CBN) from these flasks showed that 28 to 30 % of 
the Δ
9
-THC was degraded to CBN only because of the growth conditions. 
The effect of Δ
9
-THC on the growth of Catharanthus cell line was studied by 
measuring the fresh weight and dry weight of the cells fed with Δ
9
-THC for 24 
and 48 h, and compared with those of the control cells which were  treated with 
ethanol only (as control solvent) or not treated at all (control blank). The dry 
weight of the cells treated with Δ
9
-THC was significantly reduced as compared 
to the controls, which could be due to toxicity of Δ
9
-THC to the cells. A longer 
treatment with Δ
9
-THC (48h) further reduced the dry weight of the cells slightly 
(Figure 1B). 
Transformation of product 
The potential of Catharanthus roseus cell suspension culture as tool for drug 




transformation of cinobufagin was performed using cell suspension culture of 
C. roseus and its four glycosylated derivatives were identified (Ye et al. 2002). 
A B
 
Figure 1: A, Quantification of Δ9-THC (ug/ml) in media and cells after 24 and 48 hours 
of incubation. B, Total dry cell weight of CRPP incubated in 11-Glu media (Control), 
treated with EtOH and Δ9-THC for 24 and 48 hours. * depict differences between 24h 
control and cells treated with EtOH and Δ9-THC for 24 and 48 hours. Statistical icons: 
*= p< 0.05, **= p< 0.01. 
Previously, cannabinoids were transformed by using different plant cell 
cultures; however, there is no report on the use of C. roseus as a transformation 
tool for cannabinoids. The Δ
9
-Tetrahydrocannabinol (1) was transformed into 
four different derivatives named as 2, 3, 4 and 5 (Figure 2). Structures are 
proposed on the basis of molecular mass, fragmentation pattern, and 
spectroscopic data of the transformed compounds obtained from LC-MS.   


















Figure 2: Chemical structures of products 1, 2, 3, 4 and 5. 
The compound 1 was transformed to its glycosylated and further hydroxylated 
derivative 2 and 3 respectively. The positive parent ion peak at 477 [M+H]
+  
(Figure 3A) is indicating the addition of one glucose molecule to compound 1 
and its fragmentation to base peak at 315 [M+H]
+, 
suggested that 2 is composed 
of 1 and one molecule of glucose. The compound 3 eluted before 2 with a 
molecular ion peak at 493 [M+H]
+
 (Fig. 3B) proposing a  further addition of an 
hydroxyl group to compound 2. This was also confirmed by the fragmentation 
of this derivative in which 3 was fragmented to m/z 331 and 313. The positive 
peak at m/z 331 indicates the removal of a glucose molecule resulting in a 
molecular weight which is a sum of compound 1 and a hydroxyl group. After 
the hydrolysis of the EtOAc extract (medium extract), molecular peaks of m/z 
331 and m/z 315 were found. These peaks are evidence that after loss of glucose 
molecule, either 1 only or its hydroxyl derivative was present in the extract.  
The hydroxyl group is probably attached to the 5 carbon side chain or non-
phenolic ring of the product 3. Literature shows that the chromophore of the 
cannabinoids corresponds to its substituted phenolic ring, whereas alkyl-side 
chain and cyclization of non-phenolic part has no influence on the absorbance 




UV-spectrum (Figure 4, 5) but different retention times for the products 1, 2 and 
3. The elution sequence was 3, 2 and 1. 
An earlier study had revealed that 1 is quite an unstable compound at high 
temperature, light and acidic medium (Tanaka et al. 1993). This was confirmed 
by chromatographic and spectroscopic analyses which showed that after an 
exposure of 48 h to light and a temperature of 35 
°
C in the presence of 11-Glu 
media, 28-30 % of 1 was degraded into 4.  The product 4 was quantified by 
making the calibration curve of the reference compound and obtained the r
2
- 
value equal to 0.998. The positive molecular ion peak at m/z 473 [M+H]
+ 
 (Fig. 
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Figure 3: LC-MS spectra of the isolated products. A) Product 2; B): Product 3; C): 
Product 4; D): Product 5. 
glucose molecule. The MS fragmentation of 5 also confirms that m/z 473 
[M+H]
+ 
 was fragmented  to a base peak at m/z 311 [M+H]
+ 
, which is the 
molecular weight of compound 4. This assumption was also verified by the 
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acidic hydrolyses of 5 which released a glucose molecule and a molecular ion 
peak at m/z 311 was found. The UV spectrum of compound 4 (Fig. 4C) and 5 
(Fig. 4D) is similar to that of CBN reference compound (Fig. 5B). Previously, 
the tissue cultures of tubers of Pinelli ternate were reported to be able to 
transform ∆
8
-tetrahydrocannabinol and cannabinol to their glycosylated 
derivatives (Tanaka et al. 1993, 1997). Our data is in good agreement with these 
previous  reports and shows that the CRPP cell line has not only transformed 1 
but interestingly, its enzymatic system can also efficiently convert 4 to its 
glycosylated derivative. Although, 1 was degraded to 4 because of growth but 
interestingly, its enzymatic system can also efficiently convert 4 to its 




Figure 4: UV-spectra of the isolated products in the range of 190-400 nm. A)   Product 






























Figure 5: LC-MS and UV spectra of Δ9-THC and CBN reference compounds. A): Δ9-
THC UV spectra; B): CBN UV spectra; C): Δ9-THC MS spectra; D): CBN MS spectra. 
 
conditions but its further glycosylation was done in the presence of CRPP 
cultured cells. Compound 3 was the major compound indentified in the EtOAc 
extract, whereas 4 and 5 were minor compounds. The low quantity of 4 and 5 
might be due to the fast uptake of 1 leaving only very little amounts to be 
degraded into 4. Pinelli ternata tissue segments also successfully transformed 
cannabidiol and cannabidiolic acid into their glycosylated derivatives. 
Cannabidiol was transformed into cannabidiol- O-β-D-glucopyranoside and 
cannabidiol- O-β-D-diglucopyranoside. In both derivatives, glucose molecules 
were conjugated with the phenolic hydroxyl group (Tanaka et al. 1996). These 
studies suggest that the phenolic hydroxyl group is the most favorable site for 
glucose linkage in the transformation of cannabinoids. 
Conclusion 
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The rapid uptake and conversion of Δ
9
-THC into glycosylated and further 
hydroxyl derivatives shows the conversion capabilities of Catharanthus roseus 
cell suspension culture line CRPP. A growing body of literature including data 
presented in this study establishes that the glycosylation of cannabinoids is a 
common metabolic pathway in plant tissue or cell cultures. Glycosylated 
cannabinoids are phase ii reaction products in mammals and could easily be 
produced on larger scale by using cell suspension cultures of C. roseus. 
However, we incubated cells for two days after adding the substrate. Larger 
quantity of substrate and longer incubation time in dark conditions could 
minimize the substrate degradation and might be helpful to obtain a higher 
quantity of new derivatives for NMR studies. 
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6-yl]- 1-napthalenylmethanone (WIN 55,212-2) and 2-[(1R,2R,5R)-5-hydroxy-
2-(3-hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl)phenol (CP 55,940), 
and the cannabinoid antagonist (AM251). Exposures were either acute (1-12 h 
exposure at 108 hour post fertilization [hpf]); or chronic (96 h exposure starting 
at 24 hpf). Geometric range-finding was used to determine the experimental 
concentrations.  LC50 was determined based on mortality at 5 days post 
fertilisation (dpf). At day 5, behavioural analysis (visual motor response test ) 
was carried out in which movement of individual larvae was analysed using 
automated video-tracking. With acute exposure, embryos showed a biphasic 
response to the dark challenge with all three cannabinoids tested. This response 
consisted of stimulation of locomotor activity at low concentrations, 
suppression at high doses. With chronic exposure, embryos habituated to the 
effects of all three cannabinoids when assayed with the dark challenge phase. 
Furthermore, the excitation was ameliorated when the antagonist AM251 was 
co-administered with the cannabinoid. When AM251 was administered on its 
own (chronically or acutely), the locomotor activity was suppressed at high 
concentrations. We examined the embryos for a range of malformations after 
chronic exposure to cannabinoid. Only ∆
9
-THC was associated with a 
significant increase in malformations at 5d (yolk sac and pericardial oedema, 
bent tail). We conclude that cannabinoids have behavioural effects in zebrafish 
that are comparable to some of those reported in the literature for mammals. In 
particular, the acute exposure response resembles behavioural effects reported 
for adult rodents. Our data are consistent with these behavioural effects being 
mediated, at least in part, by the CB1 receptor.  




Zebrafish embryos have great promise for use in high-throughput screening of 
new drug candidates (Bull and Levin 2000, Lieschke and Currie 2007, Ali et al. 
2011,  Ali et al. 2011a, Ali et al. 2011b, Ali  et al. 2011c). The zebrafish model 
is not an alternative to rodent models in drug screening, but is complementary to 
them (Ali et al. 2011). It could be helpful in studies demanding rapid, high-
throughput and low-cost assays, such as in the early (pre-regulatory) stages of 
drug testing (Teraoka et al. 2003, Redfern et al. 2008) and also for behavioral 
testing (Best et al. 2008, Champagne et al. 2010, Rihel et al. 2010, Ali et al. 
2011a). Many basic cellular and molecular pathways regulated by different 
compounds, and by stress stimuli, are similar between the zebrafish and 
mammals (Voelker et al. 2007, Schaaf et al. 2008).  
Purification and structural elucidation of ∆
9
-THC (Gaoni  and Mechoulam  
1964) has led to the discovery of many pharmacological properties of 
cannabinoids.  ∆
9
-THC and its derivatives are being studied for their 
psychotropic properties and other pharmacological activities, including their 
possible actions as anticonvulsants, antidepressants, hypotensives, 
bronchodilators, analgesics and the ability to lower intraocular pressure 
(Holdcroft et al. 2006). Cannabinoids have also been examined for suitability in 
the symptomatic treatment of multiple sclerosis (Zajicek  et al. 2005, Baker et 
al. 2007). Unfortunately, cannabinoids may have serious, undesirable effects 
such as dependency, a possible causative association with psychotic illness, and 
cognitive impairment including deleterious effects on memory (Niyuhire et al. 
2007, Hoffman et al. 2007, Morgan et al. 2009, Cooper and Haney 2009, 
Justinova et al. 2009).  
Rodent models have been used to explore the teratological, toxicological and 




1998, Norwood et al. 2003, Drews et al. 2005, Wiley et al. 2007). Cannabinoid 
receptor type 1 (CB1) (Lolait et al. 1990), and Cannabinoid receptor type 2 
(CB2) (Munro et al. 1993) are G-protein-coupled receptors (Pertwee 2008). 
Extensive work has been done to understand their role (Rodriguez-Martin et al. 
2007, Braida et al. 2007, Migliarini and Carnevali 2009). Several previous 
studies showed that the behavioral effect of ∆
9
-THC is mediated by the central 
CB1 receptor in rats (Tseng and Craft 2004). CB1 (Lam  et al. 2006) and CB2 
(Rodriguez-Martin et al. 2007) receptors have also been reported in zebrafish. 
CB1 receptor antagonist (rimonabant) has been reported to attenuate the 
salvinorin A inducing stimulation (swimming activity) of adult zebrafish 
(Braida et al. 2007). The zebrafish, CB1 receptor appeared in the preoptic area 
at 24 hour post fertilization (hpf) (Lam et al. 2006).  
The cannabinoids used in this study (∆
9
-THC, WIN 55,212-2 and CP 55,940) 
are CB1 and CB2 agonists (Schatz et al. 1997, Pertwee 2008). A pronounced 
chronic and acute behavioral effect of cannabinoids has been observed in 
pubertal rats, which postulate that an immature brain could be more vulnerable 
to the externally exposed cannabinoid than an adult organism (Schneider et al. 
2008). The aim of this study is to determine the teratology, toxicology and 
behavioural effects of ∆
9
-THC, CP 55,940 and WIN 55,212-2 in zebrafish 
embryos. 
Material and methods  
Ethics statement 
All animal experimental procedures were conducted in accordance with local 
and international regulations. The local regulation is the Wet op de dierproeven 
(Article 9) of Dutch Law (National) and the same law administered by the 
Bureau of Animal Experiment Licensing, Leiden University (Local). This local 
regulation serves as the implementation of Guidelines on the protection of 
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experimental animals by the Council of Europe, Directive 86/609/EEC, which 
allows zebrafish embryos to be used up to the moment of free-living 
(approximately 5-7 days after fertilization). Because embryos used here were no 
more than 5 days old, no license is required by Council of Europe (1986), 
Directive 86/609/EEC or the Leiden University ethics committee. 
Animals 
Male and female adult zebrafish (Danio rerio) of AB wild type were purchased 
from Selecta Aquarium Speciaalzaak (Leiden, the Netherlands) who obtain 
stock from Europet Bernina International BV (Gemert-Bakel, the Netherlands). 
The AB strain is a wild type strain (see www.zfin.org) and shows high genetic 
diversity, increasing the likelihood that we will detect idiosyncratic responses to 
the toxins.  Fish were kept at a maximum density of 100 individuals in glass 
recirculation aquaria (L 80 cm; H 50 cm; W 46 cm) on a 14 h light: 10 h dark 





C, respectively). The fish were fed twice daily with ‘Sprirulina’ brand 
flake food (O.S.L. Marine Lab., Inc., Burlingame, USA) and twice a week with 
frozen food (artemias; Dutch Select Food, Aquadistri BV, the Netherlands). 
Defined embryo buffer 
To produce a defined and standardized control and vehicle for these 
experiments, we used 10% Hank’s balanced salt solution (made from cell-
culture tested, powdered Hank’s salts, without sodium bicarbonate, Cat. No 
H6136-10X1L, Sigma-Aldrich, St Louis, MO) at a concentration 0.98 g/L in 
Milli-Q water (resistivity = 18.2 MΩ·cm), with the addition of sodium 
bicarbonate at 0.035 g/L (Cell culture tested, Sigma Cat S5761), and adjusted to 
pH 7.46. A similar medium has been used previously in other studies (Ali et al. 





Embryo preparation was done according to Ali et al. 2011. Briefly, all 
incubations of embryos were carried out in an incubator with orbital shaking (50 
rpm) under a light cycle of 14 h light: 10 h dark (lights on at 8.00 in the 
morning). The embryos were gently transferred at 24 hours post fertilization 
(hpf) using a sterile plastic Pasteur pipette into 96-well microtitre plates (Costar 
3599, Corning Inc., NY). A single embryo was plated per well, so that embryos 
subsequently dying would not affect others; and also to allow individual 
embryos to be tracked for the whole duration of the experiment, including for 
behavioral recording.  
Cannabinoid treatment 
A significant proportion of zebrafish eggs cultured under laboratory conditions 
are either unfertilised or die within a few hours (Ali et al. 2011).  For this 
reason, we began administration of cannabinoids at 24 hpf. Purification of Δ
9
-
tetrahydrocannabinol was done by using centrifugal partition chromatography 
(Hazekamp et al. 2004). The final concentration of dimethlysulphoxide 
(DMSO) in the water was 0.01%. All pipetting was done manually, with an 8-
channel pipetter. 
Preliminary range-finding 
To determine a suitable range of concentrations for testing, we performed 
range-finding. The concentrations were in a geometric series  in which each was 
50% greater than the next lowest value (United States Environmental Protection 
Agency ,1996, Ali et al. 2011).  We used 0.0, 12.5 25.0 50.0 and 100 mg/L of 
cannabinoids. A static replacement regime was used. Thus, there was no 
refreshment of buffer after the addition of compound. Each well contained 250 
µL of either test compound or control (buffer only) or vehicle (0.01% DMSO in 
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buffer). We used 32 embryos for each concentration and 32 embryos each 
cannabinoid as control, and 32 embryos for each cannabinoid to control for the 
vehicle. The embryos for controls and treatment groups for each compound 
were plated in the same 96-well microtitre plates. 
Mortality scoring 
Mortality rate was recorded at 48, 72, 96 and 120 hpf in both range-finding and 
test concentration experiments, by examination under a dissecting 
stereomicroscope. Embryos were scored according to (Ali et al. 2011). 
Refined geometric series and LC50 determination 
After the range-finding experiments, a series of concentrations lying in the 
range between 0% and 100% mortality were selected for LC50 determination. 
The range for ∆
9
-THC and WIN 55,212-2 was 0.3-9.6 mg/L and for CP 55,940 
was 2.25-18.0 mg/L. Each geometric series of concentrations for each 
compound was repeated three times (in total 36 embryos per concentration and 
36 embryos for vehicle for each compound). The embryos for controls and 
treatment groups for each compound were plated in the same 96-well microtitre 
plates in each independent experiment. The LC50 in mg/L was then converted 
into LC50 mmol/L. The LC50 (expressed in mg/L of buffer) was determined 
based on cumulative mortality at 120 hpf using Regression Probit analysis with 
SPSS Statistics v.17.0 (SPSS Inc., Chicago, USA).  
Antagonist treatment 
A geometric series of concentrations (0.5-8 mg/L) of AM251 was used to select 
effective concentrations for further testing. These selected concentrations were 
used together with one fixed concentration of each cannabinoid. The 
concentrations of cannabinoids selected were those on which hyper-locomotor 




Chronic and acute exposure 
The exposure of cannabinoids for 96 h (24- 120 hpf) is defined as a chronic 
while for 1-12 h as acute exposure regime.  
Behavioural analysis 
The visual motor response test was performed at 5 days post fertilization (dpf) 
according to Ali et al. (2011a,  2011b) on all living larvae of both range finding 
experiments and geometric series. The test was performed in the presence of 
original solutions added at 24 h. Thus, there was no replacement or refreshment 
of buffer before test. The temperature used for testing was 28±0.5 °C. The 
visual motor response test has been previously characterized and typically 
consists of brief (less than 10 min) frequently alternating periods of light and 
dark. A key feature of this test is the robust but transient behavioral activity that 
occurs in response to sudden transitions from light to dark (Burgess and Granato  
2007, Emran et al. 2008, Macphail  et al. 2009, Rihel et al. 2010). Because such 
behavioral response has been shown to be highly sensitive to neuroactive 
chemical compounds, the visual motor response test has become a validated tool 
to assess the impact of a wider range of chemical agents on neuronal and 
physiological integrity of the developing zebrafish (Burgess and Granato 2007, 
Emran et al., 2008, Macphail et al. 2009, Rihel et al. 2010). Here we used a 
modified version of this test consisting of a single transition from light to dark. 
The activity of each larva was automatically recorded and analyzed in the 
ZebraBox recording apparatus equipped with VideoTrack software (both from 
Viewpoint S.A., Lyon, France). The white light intensity of the ZebraBox was 
500 lux. The experimental recording consists of two steps. First, larvae were 
acclimated to the behavioral setup with lights ON for 2 min. This period was 
necessary and sufficient to ensure low and stable behavioral activity. Once basal 
levels of locomotor activity were stabilized following the acclimatizing period, 
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basal swimming activity was recorded during 4 min with lights ON. This period 
is referred to as ‘basal context’. Immediately following the basal activity 
recording, the lights were suddenly turned off for 4 min. Behavioral activity in 
the dark was also automatically recorded during this period. This period is 
referred to as the ‘dark challenge context’. We chose four-minute session to 
prevent habituation, and also to favor more robust behavioral changes. Because 
of the robustness of the behavioral changes induced by varying illumination, 
this task can be used to reveal more readily than any other tasks, defective brain 
function, aberrant nervous system development and/or locomotor and visual 
defects caused by toxic compounds (Ali et al. 2011a). 
Morphological assessment of embryo phenotypes in the survivor 
population 
Morphological assessment was done according to Ali et al. (2011a). All 
embryos remained in their original multi-well plates, so that every individual 
could be tracked throughout the entire experimental and analysis procedure. The 
phenotypes were scored according to the criteria listed in Table 1. 
          Table 1. Phenotype analysis. 
Larval phenotype Criteria  
1. Normal Absence of any of the phenotypes listed below: 
2. Heart Presence of pericardial oedema  
3. Yolk Presence of yolk sac oedema 
4. Pigmentation Dispersion of melanocytes (pigment cells)  
5. Tail Tail bent 
6. Body axis Body/primary axis bent/curved 
7. Meckel’s cartilage Meckel’s cartilage grossly hypoplastic, missing or unfused in 
midline. These effects may be unilateral or bilateral. 
8. Branchial arches One or more cartilages of the branchial skeleton hypoplastic 




Description of the seven categories used to score larval phenotype at 5 dpf 
Statistical analysis  
Statistical analyses were performed using GraphPad Prism for Windows 
(version 5.03) and also used to plot graphs. To analyze the impact of 
compounds on embryo locomotion in the visual motor response test, we used 
one-way analysis of variance and a Dunnett’s Multiple comparison test with 
probability level of 5% as the minimal criterion of significance. LC50 was 
determined using Regression Probit analysis (Chi-Squares test, Pearson 
Goodness-of-fit test and 95% confidence interval) with SPSS Statistics for 
windows version. 17.0 (SPSS Inc., Chicago, USA).   
Results 
LC50 of cannabinoids 
The LC50 was determined for chronic exposure of zebrafish embryos to 
cannabinoids (96 h of exposure beginning at age 24 hpf). The following LC50 
values were obtained at 5 dpf: ∆
9
-THC, 3.37 mg/L (0.01 mmol/L); WIN 55,212-
2, 1.8 mg/L (0.003 mmol/L); and CP 55,940, 16.92 mg/L (0.049 mmol/L).  
Functional impairment at sub-lethal concentrations 
We analysed the degree of behavioural change in zebrafish embryos exposed to 
cannabinoids. We used a behavioral test, the visual motor response test, which 
relies on the integrity of the central and peripheral nervous systems, including 
the visual system, and on normal locomotor and skeletal system development. 
The effects of three cannabinoids are illustrated in Figure 1and Figure 2. 
We analysed the effects on total distance moved in the basal, challenge and 
recovery phases for both chronic and acute exposure regimes (Table 2, Table 3). 
The effects on this locomotory parameter fell into the categories of monotonic 
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stimulation; monotonic suppression; biphasic response (stimulation at lower and 
suppression at higher concentrations); or no significant effect. 




 in  basal phase 
(light on)  
Tdm in  challenge phase 
(light off) 
Tdm in recovery phase 
(light on)  





















 ∆9-THC 0.3, 0.6, 
1.2, 2.4 
- - 0.3, 0.6, 
2.4 
    - 1.2 0.3, 0.6, 
1.2, 2.4 





- - 0.3, 0.6, 
1.2 
    -   - 0.3, 0.6, 
1.2 
    -    - 
CP55, 940 2.25, 
4.5, 9 
- - 2.25, 
4.5, 9 
    -  2.25, 
4.5, 9 
    -    - 
Key: ‘=’ equal to control; ‘↓’ significantly lower than control; ‘↑’ significantly 
higher than control; ‘a’ Total distance moved; ‘b’ Concentration. 
Effect of chronic (96 h) exposure to cannabinoids on locomotor activity  
We focus here on the dark challenge phase in order to be able to make 
comparisons with studies on mammals. The term ‘chronic exposure’ is here 
arbitrarily applied to 96 h of treatment since this covers the major stages of 
organogenesis (Kimmel et al. 1995). Compared to controls, embryos exposed 
chronically to all ∆
9
-THC concentrations showed habituation (with increasing 
concentration. Only with a concentration of 1.2 mg/L was there any significant 
stimulation in the challenge phase with ∆
9







              Table 3. Concentration-dependent functional impairment by three cannabinoids (acute exposure) 
 Tdm in  basal phase 
(light on) 
Tdm in challenge phase 
(light off)  
Tdm in recovery phase 
(light on) 




































1 0.6, 1.2   - 2.4, 3.4 0.6, 3.4   - 1.2, 2.4 0.6    - 1.2, 2.4 
3.4 
4 0.6, 1.2, 
3.4 
  - 2.4 0.6, 1.2, 
2.4 
 3.4   - 0.6, 1.2, 
3.4 
   - 2.4 
12 0.6, 1.2, 
2.4 
 3.4  - - 2.4, 3.4 0.6, 1.2 0.6, 1.2, 
2.4 
  3.4 - 
1   -  0.6, 
1.2, 1.8 
 - 0.6   - 1.2, 1.8 0.6, 1.2, 
1.8 
   - - 
4 0.6, 1.8    - 1.2 0.6, 1.8   - 1.2 0.6, 1.2, 
1.8 
   - - 
12 0.6, 1.2, 
1.8 
   - - 0.6, 1.8   - 1.2 0.6, 1.2, 
1.8 
   - - 
1 2.25, 
4.5, 9 














   - 4.5 
12 18    - 2.25, 
4.5, 9 
  -   - 2.25, 
4.5, 9,  
2.25, 9, 
18 
   - 4.5 




Figure 1. Behavior analysis of live zebrafish embryos treated with Δ9-THC, WIN 
55,212-2 and CP 55,940 for 96 h. A, locomotor activity induced by Δ9-THC exposure;  
B, by  WIN 55,212-2; C, by CP 55,940. * depict differences between controls and 
different used concentrations. In figures A-C, it can be seen that there is habituation that 
occurs with 96 h exposure. The number inside the base of the bars = N embryos 
.Statistical icons: *= p< 0.05. 
Effect of acute exposure to cannabinoids on locomotor activity  
Here, acute exposure is arbitrarily applied to a 1-12 h exposure starting at 108 
hpf.  For behavioral analysis, embryos were exposed at 4.5 dpf for 12 h, and at 5 
dpf for 1-4 h (in order to provide a common endpoint of 5 d). With ∆
9
-THC, 
there was an effect of both concentration and duration of exposure on locomotor 
activity. With ≥1 h exposure time, locomotor activity was stimulated at low 
concentrations (Fig. 2A); no effect was found with high concentrations, even 




concentrations and suppression at high concentrations) was found with 12 h 
exposure (Fig. 2C). By contrast, low concentrations continued to cause hyper-
activity at 12 h exposure (Fig. 2A-C).  Concerning the other cannabinoids, the 
action of WIN 55,212-2 on locomotor activity closely resembles that of ∆
9
-THC 
and a biphasic response was found after 12 h of exposure (Fig. 2D-F). At low 
concentrations, CP 55,940 (Fig. 2G-I) and WIN 55,212-2 both gave a similar 
behaviour pattern as ∆
9
-THC (hyper-activity from 1 h - 12 h of exposure).  
Effect of exposure to the cannabinoid receptor antagonist AM251 on 
locomotor activity  
We exposed zebrafish embryos to AM251 for 1-12 h (acute exposure) or 96 h 
chronic exposure. Concentration-dependent suppression of locomotor activity 
was found in both cases (Fig. 3A-D). 
Embryos were co-exposed acutely to a cannabinoid plus antagonist (AM251) 
for 1-12 h. The antagonist caused a dose-dependent amelioration of the 














Figure 2. Behavior analysis of live zebrafish embryos treated with Δ9-THC, WIN 55,212-
2 and CP 55,940 for selected time points. The graphs represent locomotor activity at the 
following time points: A, D and G 1 h exposure with Δ9-THC, WIN 55,212-2 and CP 
55,940 respectively; B, E and H 4 h exposure with Δ9-THC, WIN 55,212-2 and CP 
55,940 respectively; C, F and I 12 h exposure with Δ9-THC, WIN 55,212-2 and CP 
55,940 respectively. * depict differences between controls and different used 
concentrations. In figures C, F and G, it can be seen that there is a biphasic response in 
acute regimes. The number inside the base of the bars = N. Statistical icons: *= p< 0.05, 









Figure 3. Behavior analysis of live zebrafish embryos treated with AM251 for selected 
timepoints. The graphs represent locomotor activity at the following time points: A, 1 h 
exposure B, 4 h; C, 12 h; D, 96 h. * depict differences between controls and different 
used concentrations. The number inside the base of the bars = N. Statistical icons: *= p< 
0.05, **= p< 0.01 and ***= p< 0.001.  




Figure 4. Behavior analysis of live zebrafish embryos co-administrated of AM251 with 
Δ9-THC, WIN 55,212-2 and CP 55,940 for selected timepoints. The graphs represent 
locomotor activity at the following time points: A, D and G 1 h exposure to AM251 
with Δ9-THC, with WIN 55,212-2 and with CP 55,940 respectively; B, E and H 4 h 
exposure to AM251 with Δ9-THC, with WIN 55,212-2 and with CP 55,940 
respectively; C, F and I 12 h exposure to AM251 with Δ9-HC, with WIN 55,212-2 and 
with CP 55,940 respectively. * depict differences between controls and different used 
concentrations.  The number inside the base of the bars = N. Statistical icons: *= p< 






Morphological assessment of embryos 
The results of morphological analysis of embryos are shown in Figure 5 and 
Table 4. With 0.3 to 2.4 mg/L ∆
9
-THC treatment, the frequency of pericardial 
and yolk sac oedemas, and bent body, were significantly higher than in control 
(buffer only) and vehicle (DMSO and buffer only) experiments. With CP 
55,940 and WIN 55,212-2 no significant increase in the frequency of any 
malformation was seen (the apparent increase in yolk sac oedema with CP 








Figure 5. Morphological assessment of zebrafish embryos at 5 dpf treated with 
cannabinoids. Zebrafish embryos stained with alcian blue reveals the ventral view. The 
aim of this figure is to show the effects on body axis of embryos after 96 h exposure to 
cannabinoids. A, control; B, vehicle; C, 1.2 mg/L Win 55,212-2; D, 9 mg/L CP 55,940; E, 
0.6 mg/L Δ9-THC; F, 2.4 mg/L Δ9-THC. PE, pericardial edema; YSE, yolk sac edema; 
BB, bent body.  
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Table 4. Statistical analysis of incidence of malformations in zebrafish embryos 












Key:* Statistical icons: (-), not significant; (*), p< 0.05; (**), p< 0.01; and 
(***), p< 0.001. Note that there were no significant increases in malformations 
after exposure to WIN 55,212 and CP 55,940. Statistical icons: *= p< 0.05, **= 
p< 0.01 and ***= p< 0.001. 
Discussion 
We have studied the effects of cannabinoids on the survival, locomotor 
activity and morphological development of zebrafish embryos. Our readouts 
were mortality recording, the visual motor response test and morphological 
analysis. Both acute and chronic exposure regimes, and the effects of the 
cannabinoid receptor antagonist (AM251), were examined.  
In acute regimes, ∆
9
-THC showed a biphasic response with increasing 
hyperactivity succeeded by suppression of activity as the dose increased. These 
findings are consistent with studies in rodents which reported a stimulation of 
locomotor activity by ∆
9
-THC at low concentrations, and suppression at higher 










Pericardial Oedema - ** * * 
Yolk sac oedema *** *** *** *** 
Bent tail  - - - - 
Body/primary axis 
(bent/curved) 
*** *** * * 
Meckel's cartilage( 
hypoplasia) 
- - - - 
Branchial arches 
(hypoplasia) 




concentrations (Grisham and Ferraro 1972, Ferraro and Gluck 1974, Taylor and 
Fennessy 1977). A recent study (Freedland  et al. 2002) suggested that high 
concentrations of ∆
9
-THC in adult rats decreased cerebral metabolism. 
According to this study, this metabolic change was associated with the biphasic 
motor behaviour of ∆
9
-THC. In zebrafish embryos, CB1 receptors are expressed 
in the preoptic area by 24 hpf (Lam et al. 2006). We therefore chose this time to 
begin chronic administration of cannabinoids. For acute exposure, we began to 
expose embryos of 4.5 dpf so that all embryos, regardless of treatment, were 
analysed at the same endpoint (day 5).   
WIN 55,212-2 also caused a biphasic response in acute regimes. This is 
consistent with findings (Drews et al. 2005) in the open field test, where rats 
treated with low concentrations of WIN 55,212-2 covered more distance than 
controls, and those treated with high concentrations covered less distance. CP 
55,940 also caused a biphasic response in acute exposure regimes. Biphasic 
locomotor activity has been reported in rats exposed to CP 55,940 (McGregor et 
al. 1996). Furthermore, a pre-treatment of CP 55,940 caused hyperactivity in 
rats subsequently exposed to morphine (Norwood  et al.  2003).  
In chronic regimes, all three cannabinoids showed habituation. It is interesting 
to notice that the habituation is probably not accompanied by general sedation 
of the embryos because their locomotor activity in the corresponding basal 
phase is normal (Table 2, Table 3). Several studies in different species have 
shown that chronic exposure of cannabinoids is accompanied by the 
development of tolerance to many of the acute effects. These effects include 
memory disorder, hypothermia and analgesia (reviewed by (Howlett et al. 
2004). In rodents, the development of tolerance to motor-behavioural effects of 
chronic cannabinoids exposure has been studied. For example, chronic exposure 
to ∆9-THC (Abood et al. 1993, Rodriguez  et al. 1994, Howlett et al. 2004), 
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WIN 55,212-2 (Martini et al. 2010) and CP 55,940 (Costa et al. 1996, Rubino et 
al. 1997) all caused tolerance to the effects of those cannabinoids on 
suppressing locomotor activity. This phenomenon was associated with down 
regulation of CB receptors after long-term exposure to cannabinoids (Abood et 
al. 1993, Rodriguez et al. 1994, Costa et al. 1996, Rubino et al. 1997, Howlett et 
al. 2004, Martini et al. 2010). Hence, the study of CB receptors expression level 
after a chronic exposure to cannabinoids can further extend our understanding 
of the phenomenon of tolerance in zebrafish embryos.  
An increased incidence of curved body axis and bent tail were found in embryos 
exposed chronically to Δ
9
-THC. It is necessary, therefore to consider the 
possibility that the changes in locomotion and behaviour were caused by these 
malformations, and not by an action of the cannabinoid on the nervous system. 
But it can be seen in Figure 1, embryos exposed chronically to Δ
9
-THC  have 
shown similar locomotor activity compared to control. Moreover, Win 55,212-2 
and CP 55,940 have not shown any significant incidence of malformations at 
any concentration tested, yet do show changes in locomotor behaviour in acute 
regimes. This suggests that the locomotor effects of these cannabinoids is not a 
secondary one due to teratogenicitiy. 
It has previously been reported in rodents that AM251 decreases the total 
distance travelled in open field test (Sink et al. 2010) and also blocks the 
locomotor excitation caused by CB1 agonists (Kongkam et al. 2008). Our data 
suggest that AM251 attenuates the increased locomotor activity induced by CB1 
agonists.  These results implicate the involvement of CB1 receptors in the 
regulation of locomotor activity in zebrafish larvae and are in good agreement 
with previous rodent studies.  
It has also been shown that AM251 attenuates the behavioural sensitization 
induced in rodents by amphetamine, nicotine and ∆
9




Thiemann et al. 2008, Le et et al. 2008). These studies show that the blockade 
of CB1 receptor not only opposes the inducing effect of cannabinoids but can 
also alter the activity of other psychotropic compounds having binding sites 
other than CB receptors.   Another study found that CP 55,940 has one, and 
WIN 55212-2 two different binding sites in the zebrafish brain (Rodriguez  et 
al. 2007). So, It would be of great interest to explore the AM251 binding 
affinity in the zebrafish brain. It is also likely that CB receptor-knockout in 
zebrafish embryos will lead to a deeper understanding of the role of CB 
receptors in zebrafish physiology. Moreover, study of agonist and antagonist 
interactions could be helpful in understanding the zebrafish endogenous 
cannabinoid system. 
Conclusions 
Our findings show that 96 h duration of exposure in zebrafish embryos starting 
at 24 hpf can be used to study the teratology of sub-lethal concentrations of 
cannabinoids. This regime also leads to habituation in behavioural response. In 
acute exposure, our findings are similar to the results found in rodents, with 
dose-dependent hyperactivity followed by suppression. The antagonist blocks 
the increased locomotor activity induced by cannabinoids. This suggests that 
some similarity in cannabinoid response pathways between zebrafish and 
mammals exists. Further validation, and study of receptor interactions, is 
needed before we can be sure that the zebrafish embryo can be a useful tool for 
the pre-clinical screening of natural, synthetic and endogenous cannabinoids.  
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Development of efficient high throughput analysis methods is a crucial 
challenge to speed up the preliminary screening of potential psychostimulants. 
In this study, we used principal component analysis in combination with 
1
HNMR to study the metabolic effects of cannabinoid receptor type 1 (CB1) 
agonist ∆
9
-THC and antagonist AM251in zebrafish embryos. The embryos were 
exposed at 24 hours post fertilization for 96 hours and analysed at 5dpf. A dose-
dependent increase was found in the levels of choline, betaine, glycine, taurine, 
ATP and glucose upon exposure to ∆
9
-THC. The levels of excitatory 
neurotransmitters glutamate and glutamine increased at lower doses of ∆
9
-THC, 
whereas the higher, lethal dose resulted in abrupt decrease of glutamate levels. 
In contrast to ∆
9
-THC, the antagonist AM251 caused a dose-dependent 
reduction in betaine, choline, taurine and also inhibited the accumulation of 
glutamate and glutamine. Interestingly, both compounds induce the production 
of the dopamine precursor’s phenylalanine and tyrosine at higher doses. These 
findings suggest that the CB1 receptor is involved in the regulation of 
metabolites, which are directly involved in neurotransmission in zebrafish 
embryos. Furthermore, our results show the importance of a 
1
HNMR based 
metabolomics platform for the preliminary screening of psychostimulants and 
pharmaceutical drugs; and in providing a detailed overview of their general 
effects on the metabolome of a whole organism. 
Introduction 
Metabolomics is a comprehensive study of a collection of the metabolites 
present in a cell, a tissue, or an organism at a particular time. It is a very useful 
tool in research efforts aimed at understanding the metabolism and related 
physiological processes at a systems biology level (Weckwerth 2003). High-
resolution proton nuclear magnetic resonance (H NMR) (1) is an ideal tool for 
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the metabolite profiling of biofluids, tissue extracts and intact tissues (Griffin 
2004) as well as mass spectrometry. 
1
HNMR spectroscopy has been used to 
investigate the biochemical composition of different tissues in an organism 
(Coen et al. 2003) and drug activity and toxicity assessment in blood serum, 
liver and testis of rodents (Ekman et al. 2006, Waters et al. 2006) as well as in 
body fluids such as serum, urine and feces (Le Gall et al. 2011, Mantle et al. 
2011). In comparison to other analytical platforms such as mass spectrometry 
coupled with liquid or gas chromatography, the attractive features of NMR are: 
simple sample preparation; non-destructive sampling; short measurement time; 
ease of quantitation and high reproducibility (Kwon et al. 2011) 
Many of the ∆
9
-THC activities depend on the interaction with cannabinoid 
receptors (CB) (Lichtman and Martin 1996). Currently, two CB receptors have 
been identified, CB1 and CB2. CB1 is expressed in brain and periphery, whereas 
CB2 is known to be expressed in immune cells and referred as periphery CB2 
receptors (Onaivi et al. 2008).   Since the discovery of CB receptors (Matsuda et 
al. 1990, Munro et al. 1993), a great deal of work has been done to find out their 
role in cannabinoids mediated activities (Alhamoruni et al. 2012, Fraga et al. 
2011, Karmaus et al. 2012). Rodent models are used to study the behavioural 
and pharmacological effects of cannabinoids (Rubio et al. 1995, Wiley et al. 
2007, Wise et al. 2011). Biphasic behavioral and physiological responses have 
been reported in rodents subjected to ∆
9
-THC (Grisham and Ferraro 1972, 
Stiglick and Kalant 1982, Taylor and Fennessy 1977). These biphasic responses 
have also been reported in the level of brain monoamines and body temperature 
(Taylor and Fennessy 1977). Previously, an HPLC method was used to analyze 
the levels of excitatory and inhibitory amino acids in the brain tissue of rats 
treated with ∆
9
-THC (Hikal et al. 1988). Here, we used NMR based 






and CB1-antagonist AM251 on metabolic profile of 5 days old post fertilization 
(5 dpf) zebrafish embryos. 
Materials and methods 
Ethics statement 
All animal experimental procedures were conducted in accordance with national 
regulations, described in the Wet op de dierproeven (article 9) of Dutch Law 
administered by the Bureau of Animal Experiment Licensing. This national 
regulation serves as the implementation of “Guidelines on the protection of 
experimental animals” by the Council of Europe (1986), Directive 86/609/EEC, 
which allows zebrafish embryos to be used up to the moment of free-living 
(approximately 5-7 dpf).  
Zebrafish handling 
Male and female adult zebrafish (Danio rerio) of wild type were purchased 
from Selecta Aquarium Speciaalzaak (Leiden, The Netherlands) which obtain 
stock from Europet Bernina International BV (Gemert-Bakel, The Netherlands). 
The fish were kept at a maximum density of 100 individuals in glass 
recirculation aquaria (L 80 cm; H 50 cm, W 46 cm) on a 14 h light: 10 h dark 






C, respectively). All the zebrafish handling was in accordance with 
national regulations. The fish were fed twice daily with ‘Sprirulina’ brand flake 
food (O.S.L. Marine Lab., Inc., and Burlingame, CA, USA) and twice a week 
with frozen food (Dutch Select Food, Aquadistri BV, Leiden, The Netherlands). 
Defined embryo buffer 
Ten percentage (v/v) of Hank’s balanced salt solution was used (made from 
cell-culture tested, powdered Hank’s salts, without sodium bicarbonate, Cat. No 
H6136-10X1L, Sigma-Aldrich, St Louis, MO, USA) at a concentration 0.98 g/L 
Metabolic effects of cannabinoids in zebrafish (Danio rerio) embryo 
121 
 
in Milli-Q water (resistivity = 18.2 MΩ·cm), with the addition of sodium 
bicarbonate at 0.035 g/L (Cell culture tested, Sigma), and adjusted to pH 7.46. 
A similar medium has been used previously (Irons et al. 2010; Macphail et al. 
2009). 
Embryo care 
Eggs were obtained by random pairwise mating of zebrafish. Three adult males 
and four females were placed together in small breeding tanks (Ehret GmbH, 
Emmendingen, Germany) the evening before eggs were required. The breeding 
tanks (L 26 cm; H 12.5 cm, W 20 cm) had mesh egg traps to prevent the eggs 
from being eaten. The eggs were harvested the following morning and 
transferred into 92 mm plastic Petri dishes (50 eggs per dish) containing 40 ml 
fresh embryo buffer. Eggs were washed four times to remove debris. Further 
unfertilized, unhealthy and dead embryos were screened under a dissecting 
microscope. At 3.5 hours post fertilization (hpf), embryos were again screened 
and any further dead and unhealthy embryos were removed. Throughout all 
procedures, the embryos and the solutions were kept at 28.5
°
C, in acclimatised 
room. All incubations of embryos were carried out in acclimatised room under a 
light cycle of 14 h light: 10 h dark.  
Preliminary range-finding 
To determine a suitable range of concentrations of testing compounds, we 
performed range-finding experiments. The concentrations were in a geometric 
series in which each was 50% greater than the next lowest value. We used 0.0, 
12.5, 25.0, 50.0 and 100 mg/L of cannabinoids. A static replacement regime 
was used. Thus, there was no refreshment of buffer after the addition of 
compound. Each well contained 250 µL of either test compound or control 
(buffer only) or vehicle (0.01% DMSO in buffer). We used 32 embryos for each 




each cannabinoid to control for the vehicle. The embryos for controls and 
treatment groups for each compound were plated in the same 96-well microtitre 
plates. 
Refined geometric series and LC50 determination 
After the range-finding experiments, a series of concentrations lying in the 
range between 0% and 100% mortality were selected for LC50 determination. 
The range for ∆
9
-THC and AM251 was 0.3-9.6 mg/L and 0.5-8 mg/L, 
respectively. Each geometric series of concentrations for each compound was 
repeated three times (in total 36 embryos per concentration and 36 embryos for 
vehicle for each compound). The embryos for controls and treatment groups for 
each compound were plated in the same 96-well microtitre plates in each 
independent experiment. The LC50 (expressed in mg/L of buffer) was 
determined based on cumulative mortality at 120 hpf using Regression Probit 
analysis with SPSS Statistics v.17.0 (SPSS Inc., Chicago, USA).  
Embryo treatment and collection 
One hundred and twenty embryos per replicate were collected. After 24 hours 
the embryo were treated with 0.6, 1.2, 2.4 and 3.4 mg/L (LC50) of ∆
9
-THC; 0.6, 
1.2, 2.4 and 4.8 mg/L (LC50) of AM251. At 5dpf, embryos were collected in 
falcon tube. The collected embryos were immediately frozen in liquid nitrogen 
and stored at -80
 °
C till further analysis. 
Sample preparation and Extraction 
A fairly simple sample preparation method already was used for plant 
metabolomics (Abdel-Farid et al. 2009, Ali Kashif et al. 2010, Jahangir et al. 
2008, Kim et al. 2010a, Kim et al. 2010b). Embryos were freeze dried and 
transferred to a micro tubes (2 ml) to which 1ml of 50% CH3OH-d4 in D2O 
(KH2PO4 buffer, pH 6.0) containing 0.01% TMSP (w/w) was added. The 
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mixture was vortexes for one min, sonicated for 20 min, and centrifuged at 
13,000 rpm at room temperature for ten minutes. An aliquot (650 µL) was then 
transferred to a 5mm-NMR tube. NMR spectra were recorded at 25°C on a 
500MHz Bruker DMX-500 spectrometer (Bruker, Karlsruhe, Germany) 
operating at a proton NMR frequency of 500.13 MHz. CH3OH-d 4 was used as 
the internal lock. each 
1
H NMR spectrum consisted of 128 scans requiring with 
the parameters as used by our group (Kim et al. 2010b). 
Data Pre Processing and Analysis 
Spectral intensities of 1H-NMR spectra were scaled to total intensity and 
reduced to integrated regions of equal width (0.04 ppm) corresponding to the 
region of δ 0.4–δ 10.0. The regions of δ 4.8–δ 4.9 and δ 3.30–δ 3.34 were 
excluded from the analysis because of the residual signal of the deuterated 
solvents. PCA was performed with the SIMCA-P software (v. 12.0, Umetrics, 
Umeå, Sweden) based on a Pareto scaling method. All of the spectra were 
referenced, base line, phase-corrected and visually inspected by superimposing 
and stacking the spectra (Fig. 1A) using MestReNova v.6.0.2 (Mestrelab 
research S.L., A Coruna, Spain).  
Results 
Principal component analysis 
Principal component analysis (PCA) is a statistical tool applied to process a 
huge number of data sets by reducing the multidimensionality of the data 
without losing required information. This technique helps to assess the possible 
differences and similarities between the samples. In order to look into overview 
of metabolic changes firstly we applied PCA to binned 
1
H NMR variables 
representing the key metabolites regulated differently in the Δ
9
-THC treated and 




enough to represent 84% of the variation in the data. The score plot shows that 
40.6% of the separation is based on PC1 and 21.8% is based on PC2 scores (Fig 
1B). Inspection of the loading plot reveals that the major source of variability 
among the samples is strongly correlated with the dose of Δ
9
-THC (Fig 1C). 
The control (HBSS) and vehicle (HBSS with 0.01% DMSO) groups tend to 
cluster together along the positive side of PC1 (horizontal line), while the most 
affected group or best separated group from the control is the medium dose 
group (1.2mg/L). The high dose (2.4 and 3.4 mg/l) groups cluster together in 
between low and medium dose (Fig 1B).  
PLS modeling with Orthogonal signal correction 
The NMR data was subjected to Partial least square data analysis (PLS-DA). A 
‘Y’ variable was included in the data representing different classes (Control, 
0.01% DMSO treated, Low dose (0.6mg/L Δ
9
-THC ), medium dose (1.2mg/L 
Δ
9
-THC), high dose (2.4mg/L Δ
9
-THC) and LC50 (3.4mg/L Δ
9
-THC), while 
each class was given a specific value. The objective of PLS-DA  modeling is to 
relate two data matrices i.e X and Y to each other by a linear multivariate model 
(Wold et al. 2001). Each class was assigned a different value as a Y variable. 
After cross validation, the model showed three components, which were enough 
to describe 57% of the variation in data. 
The PLS modeling was applied because less variation and discrepancy appeared 
in the score plot (Fig 1B), which might be because of un-correlated variables 
(metabolites), noise or systematic variations in NMR data effecting the 
separation in the score plot. To remove these uncorrelated data we developed a 
model with the use of a data filter called orthogonal signal correction (OSC). 
This filter had already been applied successfully in several studies (Gavaghan et 
al. 2002, Hauksson et al. 2001). The filter calculates a vector which is 
 














































































































Figure 1. A; Comparison of 1H NMR spectra of zebrafish embryos, showing the region 
of interest after treating the embryos with Control, 0.01% DMSO and 0.6, 1.2, 2.4 and 
3.4 mg/L of ∆9-THC. (1) Lactate (2) Alanine, (3) Acetate, (4) Glutamate (5) Choline, 
(6) Taurine, (7) Glycine, (8) Betaine, (9) Creatine, (10) Glucose, (11) ATP, (12) 
Tyrsoine, (13) Histidine, (14) Phenyalanine. B; Scatter plot from Principal component 
analysis. (C) Control, (D) 0.01% DMSO, (0.6) 0.6 mg/L ∆9-THC , (1.2) 1.2 mg/L ∆9-
THC, (2.4) 2.4 mg/L ∆9-THC, (3.4) 3.4 ∆9-THC; * represent the outlier. C; 
Representative loading plot of PCA analysis.  
orthogonal to Y and then by multiplying this vector to the loadings (represent 
the orientation of the model in the space) subtract it from X-data. This process 
removes the un-correlated data; the residual matrix left is the representative 
matrix of the variables responsible for the variation in the model. The filter was 
used before applying any model. After filtering, the data was subjected to partial 
least square analysis. The improvement in the model can be seen in Fig 2C 




applying the filter three components of the model were able to describe 95% of 
the variation. The model was validated by using the permutation test with 100 
permutations as shown in Fig 2C. Results indicate a good validation of the 
model as the intercept value of both R2Y and Q2Y are within the limits as 
described by Eriksson (2001). The scatter plot from this data shows the 
grouping of control, DMSO and low dose (0.6mg/L) treated groups on the 
negative side of PLS-DA1, while the moderate dose (1.2 mg/L) clustered on 
positive side of component 1 and negative side of component 2 (Fig 2A). The 
highest dose (3.4mg/L) group, on the other hand, belongs to the positive side of 
both component 1 and component 2.  
S-Plot 
The corresponding loading plot or S-plot shows the variables affecting the 
separation in the scatter plot (Fig 2B). The variables (
1
H NMR-chemical shifts) 
related to certain key metabolites were identified and are shown in Chapter 7, 
Table 1. The identification of metabolites confirm that the levels of amino acids 
such as glutamate, glutamine, isoleucine, alanine, threonine, aspartate, taurine, 
phenylalanine, choline, creatine and glycine are affected in embryo populations 
treated with Δ
9
-THC. The comparison of the S-plot with the Scatter plot reveals 
that the lower levels of alanine, threonine, aspartate, glutamate and glutamine 
are associated with the embryos treated with highest dose (3.4 mg/L) of 
Δ
9
-THC. The levels of phenylalanine, taurine and choline were increased in the 
samples treated with higher doses of Δ
9
-THC compared to the control group. 
Visual inspection of 
1
H NMR spectra reveals that different doses of Δ
9
-THC 
resulted in differential changes in the levels of metabolites in the embryo 
population (Fig 1A).  The levels of glucose, glutamate, acetate and adenosine 
triphosphate (ATP) increased with the increasing dose of Δ
9
-THC (0.6 to 2.4 





-THC) and decreased at the highest dose of Δ
9
-THC (3.4 mg/L). A 
dose dependent increase was observed in the level of choline, glycine and 
 
Figure 2. A; Scatter plot from Partial least square analysis with orthogonal signal 
correction filter.  Figure shows the embryos treated with Control; 0.01% DMSO; 0.6, 
1.2, 2.4 and 3.4 mg/L of ∆9-THC. * represent the outlier. B; S-Plot shows the markers 
(variables) responsible for the separation. Upper right corner correspond to the high 
doses of ∆9-THC while lower left corner correspond with the lower doses and control 
group of ∆9-THC. C; Cross validation of two components. C; validation of PLS-DA 
model with permutation test (100 permutations). 
betaine. Phenylalanine and tyrosine levels were increased at higher doses (2.4 




In additional experiments, we exposed embryos to the CB1 receptor antagonist 
AM251 (0.6, 1.2, 2.4 and 4.8 mg/L). The 24 hpf embryos were exposed for 96 h 
to the test compounds. The PCA score plot shows a clear separation of the 
groups treated with AM251 from the control group (Fig 3A). The treated groups 
were clustered to the negative side of PC1, whereas control samples had a 
positive PC1 score. This separation was based on 33% of PC1. The population 
exposed to higher (2.4 and 4.8 mg/L) and lower (0.6 and 1.2 mg/L) doses of 
AM251 were separated by PC2 (27%), having negative and positive PC2 
scores, respectively (Fig 3A). The corresponding loading column plot shows the 
differentiating metabolites responsible for the separation between treated and 
control groups (Fig 3B). The 
1
H NMR shows the signals of the discriminating 


































































































































Figure 3. A, Score plot (PC1 vs PC2) of PCA  based on whole range of 1H NMR 
signals (δ 0.3- δ 10.0) of zebrafish embryos treated with  AM 251, 0.6= 0.6 mg/L 
AM251;  1.2= 1.2 mg/L AM251;  2.4= 2.4 mg/L AM251;  4.8= 4.8 mg/L AM251 and 
C= Control (0.01% Dmso); B, Loading column plot of PC1. 1, leucine; 2, lactate; 
Metabolic effects of cannabinoids in zebrafish (Danio rerio) embryo 
129 
 
3,alanine; 4, acetate; 5 glutamine; 6, creatine; 7, choline;  
 8, glycine; 9, glutamate; 10, betaine, 11; ATP; 12, histidine. 
In the corresponding loading column plot, most of the signals are found at the 
PC1 positive side, corresponding with lower levels of the related metabolites in 
treated groups. From the 
1
H NMR signals at positive side in column loading 
plot belongs to lactate, acetate, glutamate, glutamine, choline, glycine, betaine 
and ATP, which therefore all present at lower levels in the treated embryos. The 
1
H NMR spectra (Fig 4) and loading column plot of PC2 (not shown) show 
increasing levels of phenylalanine and tyrosine in the embryo populations 
treated with higher doses (2.4 and 4.8 mg/L) of AM251. Lower doses (0.6 and 
1.2 mg/L) do not show any significant rise in phenylalanine and tyrosine levels 






















Figure 4. The 1H NMR spectra of 5 days old zebrafish embryos raised in 0.01% DMSO 
(Control) and exposed to 0.6, 1.2, 2.4 and 4.8 mg/L of AM251. 1, leucine; 2, lactate; 3, 
alanine; 4, acetate; 5, glutamate; 6, glutamine; 7, taurine; 8, glycine; 9, betaine; 10, 
creatine; 11, ATP; 12, tyrosine; 13, histidine; 14, phenylalanine. 
Discussion 
There is an extensive dataset available on the stress and drug-driven 
metabolome of mammals (Diederich et al. 1997, Milakofsky et al. 1985). These 




rodents and humans mediated by exogenous stimuli. Ethanol is reported to 
decrease the overall amino acid level in the plasma of rats (Hagman and 
Eriksson 1990, 1991). L-DOPA is known to significantly inhibit the production 
of glutamic acid and glutamine in the plasma, heart and brain stem of rats 
(Diederich et al. 1997). Aspartic acid is decreased in brain stem cells and 
plasma of rats subjected to L-DOPA and ethanol, respectively (Diederich et al. 
1997, Milakofsky et al. 1989). Here, for first time, we report the effects of 




Glutamate, choline and glycine are neurotransmitters involved in synaptic 
excitation or inhibition by acting on their respective receptors (Haga et al. 2012, 
Hollmann and Heinemann 1994, Liu J. et al. 2010, Lopez-Corcuera et al. 2001). 
Glutamate mediates synaptic excitation and inhibition by acting on N-methyl-
D-aspartate (NMDA)-sensitive ionotropic glutamate receptors (Hollmann and 
Heinemann 1994, Liu J. et al. 2010). A number of ∆
9
-THC regulated activities 
are mediated by cannabinoid receptors of the CB1 class distributed throughout 
the central nervous system and are also present on the presynaptic terminals of 
glutamatergic synapses (Wiley et al. 2005).  
In rodents, several studies have been focused on the effects of cannabinoids on 
the regulation of glutamate levels and subsequent glutamatergic 
neurotransmission (Antonelli et al. 2004, Castaldo et al. 2007, Ferraro et al. 
2001). In one study, ∆
9
-THC was shown to inhibit glutamatergic 
neurotransmission (Shen and Thayer 1999, Galanopoulos et al. 2011). In a study 
of ∆
9
-THC effect on locomotor activity in rats, a higher level of glutamate was 
found in the rat brain tissues with increased motor activity at lower dose, while 
higher doses showed habituation (Galanopoulos et al. 2011).  
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Previously, we determined the behavioral effects of ∆
9
-THC on the locomotor 
activity of 5 day old zebrafish embryos (Thesis chapter 5). In a chronic 
exposure (96 hours) to ∆
9
-THC and AM251, we found a significant locomotor 
stimulation of zebrafish embryos at the lower dose (1.2 mg/L) while a higher 
dose (2.4 mg/L) of ∆
9
-THC caused habituation. Conversely, AM251 caused a 
significant suppression of locomotor activity. In the current study, ∆
9
-THC 
induced a dose dependent increase in the levels of glutamate at doses below 
LC50 (1.2 mg/L and 2.4 mg/L) (Fig 1A). Exposure to 1.2 mg/L of ∆
9
-THC 
results in locomotor hyperactivity (Thesis Chapter 5). In contrast to ∆
9
-THC, 
AM251 produced a dose-dependent decrease in the quantity of glutamate (Fig 
4) associated with locomotor suppression (Thesis chapter 5).  
Previous data from rodent studies, together with present findings and our 
previous behavioural study, indicate an important role of CB1 receptor mediated 
glutamate regulation in the behavior of zebrafish embryos. The discovery of CB 
receptors and glutamate receptors and transporters (Gesemann et al. 2010, Rico 
et al. 2010) in zebrafish embryos, and the opposite effect of CB1 agonist and 
antagonist in the current study, together suggest a strong interaction of CB1 
receptors and glutamatergic neurotransmission in zebrafish (Tomasini et al. 
2002).  
It has been suggested that an overall increase of glutamate levels induced in 
brain tissues by ∆
9
-THC might reduce synaptic glutamate levels and 
consequently affect glutamatergic neurotransmission (Galanopoulos et al. 
2011). We have found an overall increase of glutamate levels in whole embryos 
treated with ∆
9
-THC. Therefore, in order to investigate this question further, a 
detailed study of glutamate levels in zebrafish brain tissue could provide an 
insight into ∆
9




The effects identified here on choline levels are significant because choline is 
the precursor of the neurotransmitter acetylcholine (ACh) which mediates 
cholinergic neurotransmission. Choline is metabolized into betaine which takes 
part in the biosynthesis of glycine (Friesen et al. 2007). Glycine is a mediator of 
glycinergic neurotransmission. ACh and glycine receptors have been reported in 
zebrafish embryos (Liu and Westerfield 1992, Rigo and Legendre 2006). In 
rodents, activation of CB receptors modulates cholinergic, glycinergic and 
noradrenergic neurotransmission (Szabo and Schlicker 2005). ∆
9
-THC is known 
to interact with ACh and glycine receptors (Xiong et al. 2011).  
Higher levels of choline and ACh have been found in the five brain regions of 
mice exposed to ∆
9
-THC (Tripathi et al. 1987).  However, there are also 
contradictory reports on the ∆
9
-THC modulated effects on ACh release in in 
vivo studies (Acquas et al. 2001, Gessa et al. 1998, Pisanu et al. 2006).  
Subsequently, these conflicting findings were attributed to different doses of ∆
9
-
THC used in the different studies (Solinas et al. 2007). Tzavara et al. (2003) 
reported a biphasic effect of CB1 agonist on the modulation of Ach release and 
proposed that higher doses of CB1 agonists act as an ACh depressant and lower 
doses act as a stimulator of ACh neurotransmission. ∆
9
-THC was also reported 
to activate glycine receptors in rodents, but there are no studies describing the 
effects of cannabinoids on the regulation of glycine.  The visual analyses of 
1
H 
NMR spectra reveal a dose dependent increase of choline, glycine and betaine 
in ∆
9
-THC treated embryos (Fig 1A). On the contrary, AM251 shows a dose 
dependent inhibition of choline and betaine, while a biphasic effect was found 
in case of glycine (Fig 4). Although increase in choline at the LC50 value of ∆
9
-
THC (3.4 mg/L) is contradictory to previous findings in rodents, the reciprocal 
effect of the antagonist suggests that CB1 might also play some role in the 
regulation of choline and glycine levels in zebrafish embryos.      
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Another metabolite whose levels were found to vary significantly between 
treatments in our study was phenylalanine. This is an essential amino acid and a 
precursor of tyrosine. Tyrosine hydroxylase (TH) converts tyrosine to L-
DOPA (L-3,4-dihydroxyphenylalanine) a precursor of the neurotransmitter 
dopamine. Visual inspection of 
1
H NMR spectra showed a significant increase 
of phenylalanine and tyrosine levels in the embryos exposed to higher doses of 
∆
9
-THC (2.4 and 3.4 mg/L) and AM251 (2.4 and 4.8 mg/L) (Fig 1A, Fig 4).   
A number of attempts have been made to determine the functional interaction 
between cannabinoids and dopamine neurotransmission. The presence of CB1 
receptors in TH containing cells is evidence of some connection between 
cannabinoids and catecholamine synthesis (Bosier et al. 2007). Many studies 
have shown that ∆
9
-THC elevates dopamine levels in the brain, and that this 
effect can be blocked by a CB1 receptor antagonist (Le Foll and Goldberg 
2005). ∆
9
-THC was reported to increase the TH expression in a cultured fetal 
mesencephalic cell line; by contrast, the CB1
 
receptor antagonist SR141716A 
had no such effect on TH expression. It did, however, attenuate the effect of ∆
9
-
THC on TH expression (Hernandez  et al. 2000, Hernandez et al. 1997). The 
strong correlation found in the present study between the 
1
H NMR signals of 
tyrosine and phenyalanine suggests a co-regulation of both compounds after 
exposure to ∆
9
-THC and AM251.  
An important question is the specificity of the metabolomic patterns induced by 
∆
9
-THC and AM251 in this study. That is, whether similar might be due to any 
compound exposure. This seems unlikely because we have recently examined 
the metabolic effect of solvents (DMSO and ethanol) on the 5 days old 
zebrafish embryos and found that they induce a entirely different metabolic 
profile compared to that found here for cannabinoids (Thesis chapter 7). The 




dopamine precursor (tyrosine) in cannabinoid administered embryos is not a 
general effect of drugs or solvent toxicity rather it is a specific effect of 
cannabinoid exposure on tyrosine regulation.   
Interestingly, both the CB1 receptor agonist and antagonist used here increased 
the levels of the dopamine precursor phenylalanine; this suggests that tyrosine 
might be regulated in a CB1 receptor-independent manner in the embryos. Lam 
et al. 2006 found that CB1-receptors and TH-expressing cells were co-localized 
in the caudal zone of the hypothalamus of zebrafish embryos. Together, these 
findings strengthen the possibility of cannabinoid receptor involvement in the 
regulation of the dopaminergic system in zebrafish embryos.   
Based on the current data, it is not possible to draw conclusions on the impact of 
cannabinoids on TH activity, or on the exact role of CB1 receptors in the 
regulation of tyrosine synthesis or of the dopaminergic system. Therefore, 
further molecular and functional studies are required to confirm the effects of 
cannabinoids on TH regulation and subsequently dopaminergic 
neurotranmission in zebrafish.  
In addition to neurotransmitters, several other metabolites were also 
differentially regulated by ∆
9
-THC and AM251 compared to controls. For 
example, the higher level of ATP and glucose might indicate a higher energy 
demand of the hyperactive embryos exposed to ∆
9
-THC. A dose dependent 
decrease of acetate and a biphasic effect on creatine levels was induced by 
AM251. There is no straightforward explanation of the modulation of these 
metabolites, but it is at least possible that they might play some role in 
cannabinoid induced effects in zebrafish embryo. 
Our study shows that zebrafish larvae are a useful model for performing 
metabolomic profiling in a whole animal exposed to pharmacological agents. 
This approach may help in identifying the changes a drug could elicit in 
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different biosynthetic pathways. The result of our study shows that 
cannabinoids are involved in the regulation of metabolites which are directly 
involved in neurotransmission in zebrafish embryos. Further investigations are 
needed to characterize the interactions of ∆
9
-THC with different 
neurotransmitter pathways in different regions of the zebrafish brain. Recently, 
1H NMR was used to study the metabolic profile of adult zebrafish liver (Ong 
et al. 2009). Meatbolomic studies need to be complemented by the use of 
techniques such as in situ hybridization, immunochemistry and Q-PCR in order 
to gain a complete picture of gene expression, protein distribution and 
metabolite profiles. Questions that remain to be answered are the distribution of 
CB receptors in the adult zebrafish brain, the differential roles of cannabinoid 
receptor subtypes, and the function of the zebrafish endogenous cannabinoid 
system.    
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Any bioactivity or toxicity test needs to dissolve the target compounds in an 
appropriate solvent. This is also the case in zebrafish embryo assays, an 
increasingly popular assay system in biomedical research. Water-soluble 
compounds can simply be dissolved in the aqueous medium that the zebrafish 
embryo grows in. This may be egg water (EW) or Hanks’ balanced salt solution 
(HBSS). Non-polar compounds require in addition an organic solvent. It is 
important to know whether the solvent itself – including the type of buffer - has 
an effect on the organisms or assay. Lower concentrations of some organic 
solvents have been shown to produce a pronounced change in the metabolic 
profile of an organism. For these reasons, we evaluated the effect of two 
commonly-used organic carrier solvents in drug screening: Dimethyl sulfoxide 
(DMSO) and Ethanol; and two commonly used aqueous buffers. The effects of 
three concentrations (0.01, 0.1 and 1%) of these solvents were tested on the 
metabolic profile of 5 day old zebrafish embryos. The metabolic difference was 
determined by using the 
1
H NMR based metabolomics. The zebrafish embryos 
were exposed at 24 hours post fertilization for 96 h, and then collected at 5 days 
post fertilization and analyzed by 
1
H NMR.  DMSO (0.1 and 1% but not 0.01%) 
exposure significantly decreased the level of adenosine triphosphate (ATP), 
betaine, alanine, histidine, lactate, acetate and creatine. By contrast, ethanol 
exposure did not alter the embryo metabolome at any concentration tested. We 
next examined the effect of HBSS and EW on the zebrafish embryo and found 
that the two media result in different embryo metabolomes. These results 
suggest that DMSO has relatively more pronounced effect on the embryo 
metabolome than ethanol, and used as a carrier solvent, DMSO concentration 
should be lower than 0.1%. These findings also show the significance of 
1
H 
NMR based metabolomics which can detect even a slight change in embryo 
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metabolome caused by different media, and can successfully be used for the 
identification of markers of stress- or toxicity-induced metabolic shifts.   
Introduction 
Aquatic toxicity testing of potentially hazardous chemicals is an important issue 
in environmental hazard assessment . Water solubility is the major hurdle for 
the testing of hydrophobic compounds in aqueous test systems such as, for 
example, the zebrafish model. Hydrophobic compounds have to be 
homogeneously distributed in water (Herzel and Murty 1984). Therefore, carrier 
solvents are crucial for reliable studies of a wide range of compounds (Rufli et 
al. 1998) including lipophilic compounds, in aquatic bioassays (Chen et al. 
2011). In fact, appropriate solvents for the delivery of xenobiotics is a major 
issue in in vivo toxicology studies (Nazir et al. 2003). Solvents may themselves 
affect the test organisms, leading to false positive or negative results (Rayburn 
et al. 1991). So, there is always need to analyze the effects of the solvents 
separately from that of the toxicant i.e. negative controls (Calleja and Persoone 
1993).   
For these and other reasons, it is necessary to first validate the use of carrier 
solvents before starting any toxicity study. This should result in a protocol that 
describes the type and maximum allowable concentrations (MACs) of solvents, 
which can be used in different studies without having effect on the experimental 
results.   For this, United States environmental protection agency (US EPA) has 
set a maximum acceptable limit of 0.05% for solvents for acute toxicity tests 
and of 0.01% for chronic toxicity tests (Okumura et al. 2001).  
Dimethyl sulfoxide (DMSO) and ethanol are commonly used solvents for 
hydrophobic compounds in toxicology studies. Both of these solvents have been 
used for developmental, reproductive and behavioral studies in zebrafish 




et al. 2011, Hallare A. et al. 2006, Nazir et al. 2003, Rayburn et al. 1991). These 
solvents have a great capability to solubilize a wide range of polar and nonpolar 
compounds. Therefore it is of importance to know the effects of these 
compounds on model organisms. 
The zebrafish embryo assay has been used for the screening of a growing  
library of chemicals to understand their mechanisms and the indication of 
possible acute and long term adverse effects (Ali et al. 2011, Scholz et al. 2008). 
By comparison of the metabolome of the zebrafish embryo treated with certain 
test compounds, one may learn more about the kinds of metabolic ‘signature’of 
certain drugs. For these studies, however, we need first of all to establish the 
metabolomic changes during normal development (in the absence of compound 
exposure) as well as the effect of the various carrier solvents (including the 
different aqueous buffers) used during compound exposure.  
Previously, the zebrafish embryo model was used to study the behavioral effects 
of DMSO and ethanol(Chen et al. 2011).  The effects of these solvents on the 
zebrafish embryo metabolome is not known. Here, we used nuclear magnetic 
resonance spectroscopy (NMR) based metabolomics to study the effects of 
DMSO and ethanol on the metabolic profile of zebrafish embryo.  
Materials and methods 
Ethics statement 
All animal experimental procedures were conducted in accordance with national 
regulations, which are described in the Wet op de dierproeven (article 9) of 
Dutch Law administered by the Bureau of Animal Experiment Licensing. This 
national regulation serves as the implementation of “Guidelines on the 
protection of experimental animals” by the Council of Europe (1986), Directive 
86/609/EEC, which allows zebrafish embryos to be used up to the moment of 
free-living (approximately 5-7 dpf).  




Male and female adult zebrafish (Danio rerio) of wild type were purchased 
from Selecta Aquarium Speciaalzaak (Leiden, The Netherlands) which obtain 
stock from Europet Bernina International BV (Gemert-Bakel, The Netherlands). 
The fish were kept at a maximum density of 100 individuals in glass 
recirculation aquaria (L 80 cm; H 50 cm, W 46 cm) on a 14 h light: 10 h dark 






C, respectively). All the zebrafish handling was in accordance with 
national regulations. The fish were fed twice daily with ‘Sprirulina’ brand flake 
food (O.S.L. Marine Lab., Inc., and Burlingame, CA, USA) and twice a week 
with frozen food (Dutch Select Food, Aquadistri BV, Leiden, The Netherlands).  
Defined embryo buffer 
Ten percentage (v/v) of Hank’s balanced salt solution was used (made from 
cell-culture tested, powdered Hank’s salts, without sodium bicarbonate, Cat. No 
H6136-10X1L, Sigma-Aldrich, St Louis, MO, USA) at a concentration 0.98 g/L 
in Milli-Q water (resistivity = 18.2 MΩ·cm), with the addition of sodium 
bicarbonate at 0.035 g/L (Cell culture tested, Sigma), and adjusted to pH 7.46. 
A similar medium has been used previously (Irons et al. 2010, Macphail et al. 
2009). 
Embryo care 
Eggs were obtained by random pair wise mating of zebrafish. Three adult males 
and four females were placed together in small breeding tanks (Ehret GmbH, 
Emmendingen, Germany) the evening before eggs were required. The breeding 
tanks (L 26 cm; H 12.5 cm, W 20 cm) had mesh egg traps to prevent the eggs 
from being eaten. The eggs were harvested the following morning and 




fresh embryo buffer. Eggs were washed four times to remove debris. Further 
unfertilized, unhealthy and dead embryos were screened under a dissecting 
microscope. At 3.5 hours post fertilization (hpf), embryos were again screened 
and any further dead and unhealthy embryos were removed. Throughout all 
procedures, the embryos and the solutions were kept at 28.5
°
C, in acclimatised 
room. All incubations of embryos were carried out in acclimatised room under a 
light cycle of 14 h light: 10 h dark.  
Embryo Treatment and Collection 
One hundred and twenty embryos per replicate were collected. After 24 hours 
the embryo were treated with 0.01%, 0.1% and 1% of both DMSO and ethanol. 
Embryos were collected on 5 days post fertilization (dpf) that is four days of 
exposure in falcon tube. The collected embryos were immediately frozen in 
liquid nitrogen and stored at -80
⁰
C till further analysis. 
Sample preparation and Extraction 
A fairly simple sample preparation method already was used for plant 
metabolomics (Abdel-Farid et al. 2009, Ali Kashif et al. 2010, Jahangir et al. 
2008, Kim et al. 2010a, Kim et al. 2010b, Kim et al. 2010c). Embryos were 
freeze dried and transferred to a micro tubes (2 ml) to which 1ml of 50% 
CH3OH-d4 in D2O (KH2PO4 buffer, pH 6.0) containing 0.01% TMSP (w/w) 
was added. The mixture was vortexed for one min, sonicated for 20 min, and 
centrifuged at 13,000 rpm at room temperature for ten minutes. An aliquot (650 
µL) was then transferred to a 5mm-NMR tube. 
NMR measurements 
NMR spectra were recorded at 25°C on a 500MHz Bruker DMX-500 
spectrometer (Bruker, Karlsruhe, Germany) operating at a proton NMR 
frequency of 500.13 MHz. CH3OH-d 4 was used as the internal lock. Each 
1
H 
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NMR spectrum consisted of 128 scans requiring with the parameters as used by 
our group (Kim et al. 2010c) 
Data Pre Processing and Analysis 
Spectral intensities of 1H-NMR spectra were scaled to total intensity and 
reduced to integrated regions of equal width (0.04 ppm) corresponding to the 
region of δ 0.4–δ 10.0. The regions of δ 4.8–δ 4.9 and δ 3.30–δ 3.34 were 
excluded from the analysis because of the residual signal of the deuterated 
solvents. PCA was performed with the SIMCA-P software (v. 12.0, Umetrics, 
Umeå, Sweden) based on a Pareto scaling method. Statistical analyses were 
performed using GraphPad Prism (v. 5.03 for Windows, GraphPad Software, La 
Jolla CA, USA, www.graphpad.com). We used one-way analysis of variance 
and a Dunnett’s Multiple comparison test with probability level of 5% as the 
minimal criterion of significance. All of the spectra were referenced, base line, 
phase-corrected and visually inspected by superimposing and stacking the 
spectra (Fig. 3) using MestReNova v.6.0.2 (Mestrelab research S.L., A Coruna, 
Spain).  
Results 
Effect of DMSO and Ethanol on embryos metabolome 
In this study three concentrations (0.01, 0.1 and 1 %) of DMSO and Ethanol and 
two commonly used fish media were selected to analyze their metabolic effects 
on the 5 days old zebrafish embryos. The embryos were exposed to DMSO and 
Ethanol at 24 hpf and incubated for further 96 h in Hanks balanced salt solution 
(HBSS). The broad range identification ability of NMR makes it useful tool to 
identify macro metabolites. Mostly the metabolites identified are primary 
metabolites present in living organism like amino acids, energy related 
compounds, sugars and lipids. In the aliphatic region of NMR spectra amino 




isoleucine, leucine and methionine; while organic acids like citric and lactic 
acid; bases like, creatine, choline and betaine; energy relating compounds, 
sugars like glucose and adenosine triphosphate, tyrosine and phenylalanine were 
identified. The identification of the metabolites was made by comparing the 
chemical shifts and splitting patterns with our in-house library of more than 700 
common metabolites and comparison with available literature (Foxall et al. 
1993, Govindaraju et al. 2000, Nicholson et al. 1995). The 
1
H NMR spectra of 
the control zebrafish embryos (embryos raised only in HBSS) and those 

























Figure 1. 1H NMR spectra of 5 days old zebrafish embryo treated with (a) 1% of 
DMSO in HBSS, (b) 1% of ethanol in HBSS, (c) HBSS, (d) EW (e) HBSS,. 1, Lactate; 
2, alanine; 3, acetate; 4, glutamate; 5, betaine; 6, creatine; 7, ATP; 8, Histidine; 9, 
valine; 10, glycine. 
difference is present among the kind of metabolites, while significant 
differences exist among the level of metabolites. The signals of the 
discriminating metabolites are numbered (Fig 1). These signals were identified 
and are summarized in Table 1. Some of the major contributing metabolites  
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   Table 1. Characteristic 1H NMR chemical shifts and coupling contstants of indentified 
metabolites in 5 days old zebrafish embryo. 
Metabolites Chemical shifts (δ) and Coupling constants (Hz)
Acetate δ 1.91 (s),  δ 1.97 (s)
Alanine δ 1.48 (d, J = 7.0 Hz)
ATP δ 6.13 (d, J = 5.0 Hz),  δ 8.26 (s),  δ 8.56 (s)
Betaine δ 3.29 (s),  δ 3.87 (s)
Creatine δ 3.06 (s),  δ 3.91 (s)
Glucose δ 4.60 (d, J = 7.94 Hz),  δ 5.20 (d, 4.02 Hz)
Glutamate δ 2.05 (m),  δ 2.40 (m),  δ 3.71 (m)
Glutamine 2.14,2.46,3.71
Glycine δ 3.52 (s)
Histidine δ 7.07 (s),  δ 7.84 (s),
Lactate δ 1.32(d, J= 7.0),  δ 4.06 (m)
Valine δ 1.01 (d, 7.01 Hz),  δ 1.07 (d, J= 7.1 Hz)
3 methyl histidine δ 7.05 (s)
 
were quantified and are shown in Fig. 2. The relative quantification was done 
by using the bucket data of 
1
H NMR spectroscopy with the p value <0.01. It can  
be seen in the Fig. 2, compared to control group, the quantity of alanine, 






Figure 2. Relative quantification of the major differentiating metabolites based on mean 
peak area of the realted signals. “D” symbolizes the DMSO and “E” stands for Ethanol. 
* depict the differences between control (HBSS) and the different used concentrations 
of DMSO and Ethanol. Statistical icons: *= p< 0.05, **= p< 0.01 and ***= p< 0.001. 
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reduced after exposure to 0.1  and 1% of DMSO, However, 0.01% of DMSO 
does not show any effect on these metabolites but significantly increases the 
concentration of betaine.  On the other hand, none of the ethanol concentrations 
affects any of the metabolite except betaine. 
Multivariate data analyses (MvDA) 
Principal component analysis (PCA) is a statistical technique used to analyze a 
large number of data by reducing the number of dimensions without losing 
important information.  It is an unbiased and unsupervised method, which 
represents the data in a way that allows to observe similarities and differences in 
a score plot of PCA.  The corresponding loading plot shows the chemical shifts 
of the discriminating metabolites responsible for the similarities and differences 
among the samples.  
The PCA score plot shows the projections of Control (treated only with HBSS), 
DMSO and Ethanol treated groups (Fig. 3, A). A clear separation can be seen of 
the DMSO treated samples (0.1 and 1% DMSO) from control and Ethanol 
subjected groups. The major separation is characterized by PC1. The 0.1 and 
1% DMSO samples were separated by PC2 and positioned in the positive and 
negative PC2 score, respectively. The 0.01% DMSO replicates were clustered 
more close to control having a positive PC1 score. The control and Ethanol 
groups were overlapping and placed on the positive side of PC1. The results 
show a clear metabolic change of the groups treated with higher concentrations 
of DMSO compared to control group. Whereas, there was hardly any distinction 
of metabolites observed between the control and the embryos exposed to 
Ethanol. The corresponding loading plot of the PCA was used to identify the 
1
H 
chemical shifts of the subsequent metabolites responsible for the separation in 




These results show that various solvents affect differently to zebrafish embryo 
metabolome. Dimethyl sulfoxide considerably changed the quantity of 
metabolites incubated in HBSS. To confirm these results, we also studied the 
effect of DMSO by growing the embryos in egg water containing 0.01, 0.1 and 
1% of DMSO. The PCA score plot shows the separation of 0.1 and 1% of 
DMSO from 0.01% DMSO and control (embryo raised only in Egg water) 
group (Fig. 3B). The 95% of the separation was based on PC1 score. The 0.1  
Figure 3. Score plot (PC1 vs PC2) of PCA  based on whole range of 1H NMR signals (δ 
0.3- δ 10.0) of zebrafish embryo treated with  A, .01, 0.1 and 1% of DMSO and Ethanol 
incubated in HBSS; B, .01, 0.1 and 1% of DMSO incubated in EW; C, HBSS and EW; 
D, Loading column plot of HBSS and EW. 1, valine; 2, lactate; 3, alanine; 4, acetate; 5 
glycine; 6, glutamate; 7, ATP; 8, Histidine. 
and 1% DMSO replicates were positioned on the negative, whereas 0.01% 
DMSO and control groups were overlapped on positive side of PC1.  In the 
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corresponding loading column plot (not shown) all the signals were shifted to 
the positive side. The key metabolites responsible for the separation were 
quantified and are shown in Fig. 4. The 0.1 and 1% of DMSO showed a similar 
effect in EW and decreased the quantity of all those metabolites which were 
found suppressed in embryo populations exposed to 0.1 and 1% of DMSO and 
were raised in HBSS (Fig. 1a and Fig. 4). Whereas 0.01% of DMSO did not 
affect any of the metabolite compared to control group.  
Effect of Aqueous media on embryos metabolome 
We further analyzed the effect of commonly used fish media, Hanks balanced 
salt solution (HBSS) (Adams et al. 2005, Ali et al. 2011) and Egg water (EW) 
(Hentschel et al. 2005, Watanabe et al. 2010). An apparent separation can be 
observed by the PCA score plot for the PC1 score (Fig. 3C). The zebrafish 
embryo incubated in HBSS and Egg water is positioned on the positive and 
negative side of PC1, respectively. The differentiating metabolites were 
identified on the basis of chemical shifts obtained from the loading plot (Fig. 
3D) and related signals are shown in the 
1
H NMR spectra (Fig. 1d and 1e). The 
relative quantification (not shown) of these signals showed the reduction of 
valine, alanine, lactate, acetate, betaine and glycine levels in the samples raised 
in Egg water. Whereas glutamate, ATP and histidine were lower in the embryo 
incubated in HBSS. The comparison of HBSS and EW indicates that not only 
the choice of solvent but the selection of medium is also important for the 







Figure 4.  Relative quantification of the metabolites responsible for the separation in 
PCA score plot of DMSO treated samples (incubated in EW) and EW. The 
quantification based on mean peak area of the associated signals. * depict the 
differences between control (EW) and the different used concentrations of DMSO. 
Statistical icons: *= p< 0.05, **= p< 0.01 and ***= p< 0.001. 




In the present study, we examined the effects of 4 days of exposure to low 
concentrations of DMSO and ethanol on the metabolome of zebrafish embryo, 
as well as two aqueous buffers, EW and 10% HBSS.  A significant difference 
was observed between the metabolic profiles of 
1
H NMR analyses of embryo 
populations exposed to 0.1 and 1% DMSO and control (aqueous buffer only). 
DMSO was seen to have a large effect on the various metabolite levels and were 
well separated from ethanol and the aqueous buffer group in PCA by their PC1 
and PC2 score. Particularly lower levels of amino and organic acids were 
observed in the treated groups. DMSO (0.1 and 1%) reduced the overall 
quantity of all the identified metabolites in a similar pattern. By contrast, 
ethanol did not alter the metabolite concentrations compared to control group. 
Finally, we noted that the choice of aqueous buffer (EW vs. HBSS) for raising 
zebrafish embryos had a significant effect on their metabolomic profiles.  
Previously, NMR has been used to analyze the metabolic characterization of rat 
hepatocellular carcinoma formation, rat urine and serum, and human brain 
extracts for tumor biopsies (Maxwell et al. 1998, Wang et al. 2011, Wei et al. 
2008). NMR based metabolomics and other targeted techniques (HPLC, LC-
MS, GC-MS) have also been successfully applied for the metabolic 
fingerprinting of zebrafish embryo and liver of the adult fish (Ong et al. 2009, 
Papan and Chen 2009). 
DMSO has previously been reported as a potential inducer of stress (Hallare et 
al. 2004). In a comparative study of embryotoxicity and proteotoxicity of carrier 
solvents to zebrafish embryos, DMSO at low concentrations (0.01, 0.05 and 
0.1%) was shown to significantly increase the expression of the stress-related 
protein hsp 70 (heat shock protein). Ethanol and acetone showed such an 




As can be seen in Fig. 3 and 4 we find that DMSO exposure (0.1 and 1%) 
reduced the level of adenosine triphosphate (ATP). This is consistent with 
previous findings. Thus, it was reported that DMSO (0.1%) exposure, coupled 
with the inhibition of cytochrome P450 (CYPs) in zebrafish embryos, reduces 
the level of ATP in zebrafish ovarian follicles and fragments (David et al. 2012, 
Zampolla et al. 2009, Zampolla et al. 2011). CYP enzymes play an important 
role in the oxidative metabolism of endogenous and exogenous substances 
(Buhler and Wang-Buhler 1998). A further study found that in the kidneys of 
male wistar rats, DMSO reduced the level of ATP and slowed down the process 
of glycolysis by activating the FDPase (Fructose 1,6-diphaphatase) (Baxter and 
Lathe 1971). 
Taken together, our results and previous findings could suggest that DMSO 
may cause a metabolic inhibition leading to greatly reduced levels of ATP, and 
in turn the suppression of primary metabolite levels in the zebrafish embryo. 
Further studies (including also, for example, proteomics and transcriptomics) 
are needed to confirm this hypothesis. What is perhaps surprising in our study is 
that ethanol exposure (0.01, 0.1 and 1.0%) had no significant effect on the 
zebrafish embryo metabolome, even though it is known to be a potent teratogen 
(Arenzana et al. 2006). These studies showed that even low concentrations of 
ethanol (0.05, 0.1 and 1%) can induce the hyper locomotor activity in zebrafish 
embryos (Echevarria et al. 2010). In a study of behavioral and teratological 
effects of ethanol on zebrafish larave, 0.01 and 0.1% of ethanol was found safe 
in not producing any developmental defect but still inducing hyper locomotion 
(Chen et al. 2011). By contrast, 1% ethanol not only altered the locomotor 
activity but also significantly increased the incidence of e.g pericardial edema, 
yolk sac edema, crooked body and cyclopia (Arenzana et al. 2006, Chen et al. 
2011).  
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An interesting question is why, in our study, DMSO had such a pronounced 
metabolic effect, while previous studies showed it to have only mild phenotypic 
effects on embryos; while in contrast, ethanol had no effect on the metabolome 
in our study, even though it is known to have pronounced phenotypic effects on 
embryo development.  The answer may lie in the fact that DMSO is known to 
produce pronounced effects on the liver enzymes and ATP production which 
might cause the large effect on embryo metabolism seen in our study. The use 
of DMSO should therefore be evaluated carefully, and the final concentration 
should be as low as possible; the concentration of 0.01% DMSO in either EW  
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         Figure 5: Score plot (PC1 vs PC2) of PCA  based on whole range of 1H NMR signals 
(δ 0.3- δ 10.0) of zebrafish embryo treated with Ethanol (0.01, 0.1 and 1%) raised in     
HBSS, DMSO (0.01, 0.1 and 1%) raised in HBSS and EW, raised only in HBSS and 
EW. 




Moreover, our findings suggest that the selection of the aqueous medium is also 
important because it may affect embryo metabolism. Given a fixed 
concentration of DMSO (0.01), the metabolic effect varies according to whether 
this concentration of DMSO was in HBSS or EW. It can be seen in the PCA 
analysis of all samples shown in Fig. 5 that, all three ethanol concentrations, 
0.01% DMSO in HBSS and HBSS alone, were all clustered on the positive side 
of PC1. EW alone, and 0.01% of DMSO in EW replicates overlapped and had 
positive PC1 and PC2 scores. The points for DMSO (0.1%) in HBSS, and those 
for DMSO (0.1%) in EW, were separated by a small distance having negative 
PC1 score. Interestingly, the 1% DMSO samples (raised in either HBSS or EW) 
were found to cluster tightly together. Therefore, at this concentration of 
DMSO, the choice of aqueous medium no longer has an effect.   
Conclusion 
Our results demonstrate that NMR together with multivariate data analyses 
provides comprehensive information of amino and organic acids in the 5 dpf 
zebrafish embryo metabolome. NMR can successfully detect a even slight 
differences in metabolite levels induced by aqueous media or organic solvents, 
respectively.  The study also shows that zebrafish embryos can be used for the 
preliminary screening of compounds by providing insight into the metabolic 
changes mediated by drugs or toxins. Finally, we recommend that for 
metabolomic studies of zebrafish embryos, the DMSO concentration should be 
lower than 0.1%.    
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Cannabinoids are a group of terpenophenolic compounds containing a C1, C3 or 





-THC) is the psychoactive cannabinoid. It is an 
approved stimulant of appetite and antiemesis in patients under chemotherapy 
and HIV therapy regimes and is used to treat a number of disease states 
including pain, anxiety, asthma, glaucoma and hypertension. There is a growing 
interest in developing new derivatives of Δ
9
-THC with high medicinal value. 
The high lipophilicity of Δ
9
-THC is hindering the further development of this 
compound into a pharmaceutical product. The human body contains high lipid 
contents, which are not only the body fats but also present in brain and cell 
membranes. ∆
9
-THC binds strongly to plasma protein and other fatty tissues, 
which prolongs its release from the body. So, there is a need to structurally 
transform the compound to increase its polarity and its rapid release from the 
body. This thesis is focused on investigating the biotransformation potential of 
alkane degrading bacterial strains and Catharanthus roseus  plant cell culture to 
produce more polar derivatives of Δ
9
-THC to facilitate rapid release of the drug 
from the body. 
In chapter 2 we reviewed a large library of Δ
9
-THC metabolites developed 
through bioconversions with mammalian, fungal, bacterial and plant cell 
cultures.  These organisms have unique enzymes which catalyzed the 
conversion of Δ
9
-THC at different positions and thus provide a source for a 
variety of derivatives. These compounds can be used to obtain a wealth of 
information about the pharmacodynamics and pharmacokinetics of Δ
9
-THC and 
thus pave the way to the discovery of new compounds, with improved 
therapeutic properties.  
In an effort to generate highly polar derivatives of Δ
9
-THC, we screened 206 
alkane degrading bacterial strains. The alkyl side chain of Δ
9




the specific target site for alkane degrading bacteria to convert it into more polar 
derivatives. Gram-positive strains from the genera Rhodococcus, 
Mycobacterium, Gordonia, and Dietzia were found to be most efficient in 
transformation of Δ
9
-THC. In total, eight derivatives were produced on a mg 
scale. All of these transformants possessed modified alkyl chains, with hydroxy, 
carboxy and ester functionalities (Chapter 3). 
Besides microorganisms, plant cell cultures also act as suitable biocatalysts to 
perform complex biochemical reactions. The enzymatic system of plant cells 
can successfully convert the exogenously applied substrates into novel and 
valuable products with improved properties regarding stability, bio-activity and 
solubility. We investigated the potential of cell suspension culture of 
Catharanthus roseus to transform Δ
9
-THC. Unlike bacterial strains, 
Catharanthus roseus cells transformed Δ
9
-THC to its glycosylated and 
additionally hydroxylated derivatives. Δ
9
-THC was found to be degraded into 
cannabinol (CBN) which was also converted to its glycosylated derivative. Our 
findings suggest that microorganisms and plant cell cultures have different 
Cytochrome P450 enzymes and consequently results into different metabolic 
pathways for Δ
9
-THC (Chapter 4).  
The zebrafish embryo holds great promise for high-throughput screening of new 
drug candidates. It could be helpful for a rapid, high-throughput and low-cost 
assays, e.g. in the early (pre-regulatory) stages of drug testing and also for 
behavioral testing. The behavioral effect of ∆
9
-THC is mediated by the central 
CB1 receptor in rats. The discovery of CB receptors in zebrafish embryos can 
be helpful to gain further insight in the pharmacology of cannabinoids and it 
might also be helpful to resolve some unclear features of the cannabinoids mode 
of action, like the phenomenon of tolerance and dependence caused by 






HNMR based metabolomic approach in order to study the cannabinoid 
associated phenotypic, behavioral and metabolic effects in zebrafish embryos.  
Chapter 5 reports the effects of the cannabinoids ∆
9
-THC, WIN 55,212-2 and 
CP 55,940, and the cannabinoid antagonist (Am 251) on zebrafish embryo 
locomotor activity. We found a significant similarity between physiological 
responses of rodents and zebrafish embryos to cannabinoids. The zebrafish 
embryo seems to be a reliable behavioral model and could provide new 
opportunities for the preliminary screening of psychoactive compounds. 
High-resolution proton nuclear magnetic resonance (
1
H NMR) is an ideal tool 
for the metabolite profiling of biofluids, tissue extracts and intact tissues. It 
has been used to investigate the biochemical composition of different tissues 
in an organism and drug toxicity assessment in blood serum, liver and testis of 
rodents. We have successfully applied 
1
H NMR in combination with 
Multivariate data analyses for the metabolite profiling of 5 days old 
fertilization (5dpf) zebrafish embryos. Embryos exposure to ∆
9
-THC and 
AM251 showed a pronounced effect on the metabolites which are directly 
involved in neurotransmission. The opposed effects of ∆
9
-THC and AM251 
indicate the involvement of CB1 receptors in ∆
9
-THC regulated metabolites in 
zebrafish embryos. Our findings suggest that zebrafish embryos can be used as 
a model organism to study the metabolic signatures of certain drugs (Chapter 
6).      
The bioassays are based on the solvents to solubilize the hydrophobic 
experimental drugs. Water-soluble compounds can simply be dissolved in the 
aqueous medium used to culture different experimental cells or organisms. It is 
important to know whether the solvent itself – including the type of buffer - has 
an effect on the organisms, cells or assay. For this reason, we assessed the 




commonly used aqueous buffers (HBSS and EW) in which zebrafish embryos 
are grown. Dimethyl sulfoxide (DMSO) significantly decreased the level of 
many primary metabolites. Whereas, ethanol did not alter the embryos 
metabolome at any concentration tested. Likewise, both the aqueous buffers 
also resulted in entirely different embryos metabolome. Taken together, these 
results show that a critical evaluation of carrier solvents and aqueous medium is 
important to avoid false negative results. Particularly in case of zebrafish 
embryos metabolomic studies, DMSO has a relatively more pronounced effect 
than ethanol and used as a carrier solvent, DMSO concentration should be lower 
than 0.01%. Morevover, 
1
H NMR based metabolomics can successfully be 
applied for the identification of markers of stress- or toxicity-induced metabolic 
shifts (Chapter 7).   
In conclusion, considering the aims of the thesis it has been shown: 
that bacterial cell culture and  also plant cell culteres are a promising tool for the 
large scale production of highly polar derivatives of ∆
9
-THC. Further evaluation 
of these derivatives with respect to their binding affinity for CB receptors could 
be helpful in understanding the pharmacological properties of these more polar 
metabolites. .  
- To develop novel tools to measure cannabinoids in-vivo assays 
studying the behavioral effects on zebrafish embryos/larvae, using the visual 
motor response test proved to be useful. A similar physiological response of 
zebrafish embryos to cannabinoids was found as reported for rodents. The 
zebrafish embryo can be applied early in the drug discovery pipeline and early 







A number of studies on the metabolic pathways of THC in several mammalian 
species have led to the discovery of a large collection of THC metabolites. 
Microorganisms and plant cell cultures have proved to be efficient sources for 
the large scale production of polar derivatives of THC. However, only a small 
fraction of these THC derivatives have been evaluated pharmacologically and 
the medicinal potential of a large proportion of these compounds still remains to 
be fully explored. The derivatives with differential binding affinities to CB 
receptors or relatively weaker binding affinities are particularly attractive in this 
regard as these might possess interesting pharmacological promise including the 
opportunity to develop drugs that are more specific and have less side effects.  
Although zebrafish embryos have shown a rodent-like physiological response to 
CB1 agonists and antagonists, still much work remains to be done to fully assess 
their role as an alternative model system to study different aspects of 
cannabinoid pharmacology. Particularly the question of the different functions 
of the two known cannabinoid receptors in humans translates to zebrafish will 
be of interest to study in more detail. Amongst the issues that require particular 
attention in this regard, are the amino acid sequence homology of zebrafish, 
human and rodent CB receptors, distribution and expression levels of CB 
receptors at different stages of zebrafish development and study of other 
receptors that might interact with cannabinoids such as the G protein-coupled 
receptor 55 (GPR55) in rodents (Pertwee 2007). Future research along these 
lines would lead to a more comprehensive understanding the effects of natural, 
synthetic and endogenous cannabinoids in zebrafish. Moreover, combining 
molecular techniques like in-situ hybridization (ISH), quantitative PCR (qPCR) 




usefulness of zebrafish as a model system but would also further improve our 
understanding of cannabinoid associated effects on animal physiology.   
In conclusion, future explorations of zebrafish for pharmacokinetic studies of a 
plethora of psychoactive and non-psychoactive cannabinoids holds great 
promise for the field. This promise will certainly be further boosted by 
combining the classical genetic methods, state of the art molecular techniques 
and cutting edge metabolomic technologies such as NMR and LC/GC-MS with 
the high throughput that zebrafish embryos offer.  
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Cannabinoïden vormen een groep van terpenophenolische verbindingen die 
enkel te vinden zijn in de Cannabis plant.(Cannabis sativa L). Δ9-
tetrahydrocannabinol (Δ
9
-THC) is de psychoactieve cannabinoïde. Het is 
pharmacologisch erkend voor de stimulatie van eetlust en werkt als 
antiemeticum bij patiënten met chemotherapie en HIV therapie en wordt verder 
gebruikt voor indicaties zoals  pijn, MS, glaucoom en Tourette syndroom. Er is 
een groeiende belangstelling voor het ontwikkelen van nieuwe derivaten van 
Δ
9
-THC met een hoge geneeskrachtige waarde. Echter, de hoge lipofiliteit van 
Δ
9
-THC is een belemmering voor de verdere ontwikkeling van deze verbinding 
in een farmaceutisch product. Het menselijke lichaam heeft een hoog 
vetgehalte, niet alleen in  het vetweefsel in het lichaam, maar ook in de hersenen 
en celmembranen. Δ
9
-THC bindt sterk aan plasma eiwitten en aan vetweefsel, 
waardoor de uitscheiding uit het lichaam significant wordt verlengd. Het is dus 
noodzakelijk om de polariteit van de cannabinoïden  te verhogen om een snelle 
afgifte uit het lichaam te verkrijgen. Dit proefschrift is gericht op het onderzoek 
van de mogelijke biotransformatie van cannabinoïden in  meer polaire derivaten 
van Δ
9
-THC door alkaan afbrekende bacteriën en Catharanthus roseus 
plantencellen. 
In hoofdstuk 2 hebben we een bibliotheek van Δ
9
-THC metabolieten 
ontwikkeld door middel van bioconversies met celculturen van zoogdieren, 
schimmels, bacteriën en planten. Deze organismen hebben unieke enzymen die 
de omzetting van Δ
9
-THC mogelijk katalyseren en die op verschillende plaatsen 
in het molecuul kunnen aangrijpen, en derhalve een bron zijn voor een 
verscheidenheid van derivaten. Deze verbindingen kunnen worden gebruikt om 
meer informatie over de farmacodynamiek en farmacokinetiek van Δ
9
-THC te 
verkrijgen en aldus de weg vrijmaken voor de ontdekking van nieuwe 




In een poging om sterk polaire derivaten van Δ
9
-THC te genereren hebben we 
206 alkaan afbrekende bacteriestammen gescreend. De C5-alkylzijketen bleek 
de specifieke target site die alkaan afbrekende bacteriën gebruiken om Δ
9
-THC 
om te zetten in meer polaire derivaten. Met name Gram-positieve stammen van 
de geslachten Rhodococcus, Mycobacterium, Gordonia en Dietzia bleken 
efficiënt in transformatie van Δ
9
-THC. In totaal werden acht derivaten 
geproduceerd op milligram schaal. Al de eproduceerde transformatie producten 
hebben een gemodificeerde alkylketes met hydroxy, carboxy en ester 
functionaliteiten (hoofdstuk 3). 
Naast micro-organismen, kunnen ook planten celcultures fungeren als 
biokatalysatoren om complexe biochemische reacties uit te voeren. Het 
enzymatische systeem van plantencellen kan vaak met succes exogeen 
toegepaste substraten omzetten naar nieuwe en waardevolle producten met 
verbeterde eigenschappen met betrekking tot de stabiliteit, bio-activiteit en 
oplosbaarheid. We onderzochten het potentieel van celsuspensiekweek van 
Catharanthus roseus voor de bioconversie van Δ
9
-THC. Anders dan 
bacteriestammen, glycosyleren Catharanthus roseus cellen Δ
9
-THC.  
Bovendien hydroxyleren ze cannabinoiden. In de celculture werd Δ
9
-THC ook 
afgebroken tot cannabinol (CBN), dat vervolgens ook werd omgezet in zijn 
geglycosyleerde derivaten. Onze bevindingen suggereren dat micro-organismen 
en plantencelkweken verschillende cytochroom P450 enzymen bevatten en dat 
resulteert in verschillende catabole routes hebben voor Δ
9
-THC (Hoofdstuk 4). 
Het zebravis embryo bioassay model lijkt zeer geschikt voor high-throughput 
screening van nieuwe kandidaat-geneesmiddelen. Het maakt snelle, high-
throughput en goedkope assays mogelijk, zoals voor het in vroege (pre-
regulering) stadia testen van geneesmiddelen en voor gedrags testen. De 
gedragseffecten van Δ
9




receptor. De ontdekking van CB receptoren in zebravis embryo's kan nuttig zijn 
om meer inzicht te krijgen in de farmacologie van cannabinoïden. Het kan ook 
nuttig zijn om een aantal onduidelijke aspecten van het cannabinoïden 
werkingsmechanisme, zoals het fenomeen van mogelijke tolerantie en 
afhankelijkheid veroorzaakt door cannabinoïd-gebaseerde geneesmiddelen te 
onderzoeken . We gebruikten  kleuringen, visueel motorische respons test en 
1H-NMR gebaseerde metabolomics  om de fenotypische, gedrags- en metabole 
effecten van  cannabinoïden in de zebravis embryo's te bestuderen. 
Hoofdstuk 5 beschrijft de effecten van het natuurlijke cannabinoïd Δ
9
-THC, en 
de synthetische cannabinoïden WIN 55,212-2 en CP 55940, en de cannabinoïd 
antagonist Am 251 op zebravis embryo motorische activiteit. We vonden een 
significante overeenkomst tussen fysiologische reacties van knaagdieren en 
zebravis embryo’s op deze cannabinoïden. Het zebravis embryo lijkt daarom 
een betrouwbaar gedragsmodel voor het testen van deze psychoactieve 
verbindingen. 
High-resolution proton nucleaire magnetische resonantie (1H-NMR) is een 
ideaal  hulpmiddel voor het profileren van de metabolieten in  biovloeistoffen, 
weefsel extracten en zelfs in intacte weefsels. Het is onder andere gebruikt om 
de biochemische samenstelling van verschillende weefsels te onderzoeken in 
een organisme en voor het bepalen van geneesmiddeltoxiciteit door analyse van 
bloedserum, lever en testis van knaagdieren. We hebben met succes 1H-NMR 
in combinatie met multivariate data-analyse toegepast voor de metaboliet 
profilering van zebravis embryos op 5 dagen na bevruchting (5dpf). 
Blootstelling van embryos aan Δ
9
-THC en AM251 leidde tot een uitgesproken 
effect op de metabolieten die direct betrokken zijn bij neurotransmissie. De 
tegengestelde effecten van Δ
9
-THC en AM251 laten zien dat  de CB1-




suggereren dat zebravisembryos kunnen worden gebruikt als modelorganisme 
om de metabole “footprint” van bepaalde geneesmiddelen (hoofdstuk 6) te 
bestuderen. 
In de bioassays worden organische oplosmiddelen gebruikt om hydrofobe test 
stoffen op te lossen. Water oplosbare verbindingen kunnen eenvoudig worden 
opgelost in het waterige kweek medium  van de verschillende experimentele 
cellen of organismen. Het is echter belangrijk te weten of het oplosmiddel zelf - 
inclusief het type buffer - een effect op de organismen, cellen of assay heeft. 
Daarom hebben we de metabole effecten gemeten van de meest gebruikte 
organische oplosmiddelen (dimethylsulfoxide, ethanol) en de  twee gebruikte 
waterige buffers (HBSS en EW) waarin zebravis embryos worden gekweekt. 
Dimethylsulfoxide (DMSO) geeft een significant verlaagd niveau van veel 
primaire metabolieten. Ethanol heeft daarentegen geen invloed op het embryo's 
metaboloom bij de geteste concentraties. Ook beide waterige buffers leiden  tot 
verschillende embryo metabolomen. Tezamen tonen deze resultaten dat een 
kritische evaluatie van carrier stoffen en waterige media  belangrijk is om vals 
negatieve resultaten te voorkomen . Vooral bij zebravis embryo, heeft DMSO 
relatief een sterker effect op metabolietvorming dan ethanol heeft. Als drager 
oplosmiddel dienen DMSO concentraties lager te zijn dan 0,01%. 1H-NMR 
gebaseerde metabolomics kan met  succes worden toegepast voor het in kaart 
bregen van metabolische veranderingen, bijvoorbeeld voor de identificatie van 
markers van stress-geïnduceerde toxiciteit (hoofdstuk 7). 
Concluderend, in relatie tot de doelstellingen van het proefschrift werd 
aangetoond dat: 
- het gebruik van bacterieën en plantencelcultures is veelbelovend voor de 




van deze derivaten met betrekking tot hun bindingsaffiniteit voor CB-receptoren 
zou kunnen helpen bij het begrijpen van de farmacologische eigenschappen van 
deze polaire metabolieten.  
- Bij het volgen van het gedrag van zebravis embryos / larven, met behulp van 
de visuele motorische respons test bleek dat embryo’s een vergelijkbare 
fysiologische respons geven als knaagdieren na toedienen van  cannabinoïden. 
Dit betekent mogelijk dat de zebravis embryos kunnen worden toegepast in het 
begin van de drug discovery pijplijn en bij de beoordeling van de veiligheid van 
geneesmiddelen, zoals bijvoorbeeld voor nieuwe cannabinoïde agonisten en 
antagonisten. 
Toekomstperspectieven 
Een aantal studies naar de catabole routes van THC in verschillende soorten 
zoogdieren hebben geleid tot de ontdekking van een groot aantal THC 
metabolieten. Micro-organismen en plantencel cultures bleken geschikt voor de 
grootschalige productie van polaire derivaten van THC. Echter, slechts een 
klein deel van deze THC-derivaten zijn farmacologisch geëvalueerd en de 
therapeutische mogelijkheden van een groot deel van deze verbindingen moeten 
nog worden onderzocht. Derivaten met verschillende bindingsaffiniteiten aan 
CB receptoren of met een relatief zwakke bindingsaffiniteit zijn  interessant, 
met inbegrip van de mogelijkheid om geneesmiddelen te ontwikkelen die 
specifieker zijn en minder bijwerkingen hebben. 
Hoewel zebravis embryos een knaagdier-achtige fysiologische respons hebben 
op CB1-agonisten en antagonisten, moet er nog veel werk worden gedaan om 
hun mogelijkheden  als een alternatief model systeem in de cannabinoïde 
farmacologie volledig te kunnen beoordelen . Met name de vraag hoe de 




zich vertalen  naar het  zebravis model  is van belang. Onder de problemen die 
bijzondere aandacht in dit verband vereisen, zijn de aminozuursequentie 
homologie van zebravis, menselijke en knaagdieren CB receptoren; de 
verdeling en expressie van CB-receptoren in verschillende stadia van 
ontwikkeling van de zebravis; en de interactie van andere receptoren met de 
cannabinoïden  G-eiwit-gekoppelde receptor 55 (GPR55) in knaagdieren 
(Pertwee 2007). Toekomstig onderzoek langs deze lijn zou kunnen leiden tot 
een meer omvattend begrip van de effecten van natuurlijke, synthetische en 
endogene cannabinoïden in de zebravis. Bovendien zou een combinatie van 
moleculaire technieken zoals in situ hybridisatie (ISH), kwantitatieve PCR 
(qPCR) en de kleuring van embryos niet alleen verder het nut van de zebravis 
als modelsysteem bewijzen, maar ook het  begrip verbeteren van cannabinoïde 
geassocieerde effecten in de dierfysiologie. 
Tot slot, het gebruik van de zebravis voor farmacokinetische studies naar 
nieuwe psychoactieve en niet-psychoactieve cannabinoïden houdt een grote 
belofte in voor nieuwe geneesmiddelen. Deze belofte zal zeker verder worden 
versterkt door het combineren van de klassieke genetische methoden, state-of-
the-art moleculaire technieken en geavanceerde metabolomics technologieën 
gebaseerd op NMR of  LC / GC-MS met de hoge doorvoer van analses die 
zebravis embryos mogelijk maken. 
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